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ABSTRACT 
John David Casachahua: The Role of Cytokines in Binge-Like Ethanol Consumption and 
Ethanol-induced Sedation 
(Under the direction of Todd E.Thiele and Donald T. Lysle) 
 
There is a growing body of research that is establishing a prominent role for the immune 
system in the brain. Recent studies have demonstrated a role for immune system messenger 
cytokines in modulating binge-like ethanol consumption. The goal of this dissertation is to 
examine the roles of proinflammatory cytokines, specifically IL-6, in binge-like ethanol 
consumption and ethanol-induced sedation. The experiments of Chapter 2 characterized the 
expression of IL-6 in the central amygdala, paraventricular nucleus of the hypothalamus (PVN), 
and other candidate regions of the brain in response to binge-like ethanol consumption through 
use of the “Drinking in the Dark” (DID) protocol followed by immunohistochemical procedures 
examining IL-6 immunoreactivity in the candidate regions of the brain. The most promising 
region of interest was the central amygdala (CEA), and in Chapter 3, experiments were 
performed with site-directed infusions of IL-6 receptor antagonist into the CEA to alter 
proinflammatory cytokine signaling and modulate binge-like ethanol consumption. These IL-6 
receptor antagonists that were site-specifically administered on the test day on the third cycle of 
the DID protocol with ethanol reduced binge-like ethanol consumption. Following up on these 
findings were sucrose DID tests that were used to determine that consumption in general was not 
reduced by the application of this cytokine antagonist. Chapter 4 describes the experiments that 
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were run to assess whether IL-6 specifically modulated ethanol’s sedative/ataxic properties, 
through the use of site-directed infusions of IL-6 receptor antagonist employed to alter 
proinflammatory cytokine signaling in the central amygdala. Mice were exposed to an 
intraperitoneal ethanol administration followed by the application of the IL-6 receptor antagonist. 
Subsequent to this protocol, mice were tested on their motor reflexes with a rotarod apparatus to 
determine the antagonist’s impact on ethanol-induced sedation. Here it was established that IL-6 
does not appear to modulate ethanol’s sedative/ataxic properties. Together, these experiments 
indicate that IL-6 signaling critically modulates binge-like ethanol consumption after a history of 
binge-like ethanol consumption. The results suggest a potential therapeutic value for IL-6 
antagonism in the reduction of binge ethanol drinking and a prophylactic approach against 
ethanol dependence. 
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Chapter 1 
General Introduction 
 
Human binge ethanol drinking and the mouse model, “Drinking in the dark” 
NIAAA (2004) defines binge drinking as a pattern of drinking leading to blood ethanol 
concentrations of greater than 0.08% or 80 mg/dl. This translates to be 4 to 5 drinks in 2 hours 
for the average adult. This pattern of drinking is most prevalent in both adolescent and adult 
populations. According to the Substance Abuse and Mental Health Services Administration’s 
2014 National Survey on Drug Use and Health, 24.7 % of adults aged 18 or older and 37.9% of 
college students aged 18-22 have engaged in binge drinking alcohol within the month of their 
survey. This binge drinking behavior increases the risk of accidental injury, increases mood 
disorders, increases aggressive and violent behavior, and impairs decision making and judgment 
(Gmel et al, 2006; Okoro et al., 2004; Shepherd et al., 2006; & Goudriaan et al., 2007). Heavy, 
prolonged binge drinking has been linked to long-term health consequences including heart 
disease, high blood pressure, and type 2 diabetes (Fan, Russell, Stranges, Dorn, & Trevisan, 
2008). Furthermore, there is an increased risk for developing alcohol dependence in individuals 
that binge drink frequently (Courtney & Polich, 2009). Following the US Public Health Service 
guidelines, the estimated cost of excessive alcohol drinking in 2006 was $223.5 billion, with 
76.4% or $170.7 billion in costs from binge drinking alone (Bouchery et al., 2011). A follow-up 
study published in 2015 reported that the estimated cost of excessive alcohol drinking in 2010 
was $249 billion, with 76.7% or $191.1 billion in costs from binge drinking alone, which reflects 
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an escalating impact these abusive behaviors are having on this nation (Sacks, Gonzales, 
Bouchery, Tomedi, & Brewer, 2015). 
The “Drinking in the dark” (DID) procedure is an established mouse model of binge 
ethanol drinking developed by Rhodes and Colleagues (2005). For this procedure, 3 hours into 
the dark cycle mice have their water bottles replaced with 20% ethanol for 2 hours on days 1-3 
for habituation, and for 4 hours on the day 4 Binge Test. Strong evidence that supports the face 
validity of this binge drinking animal model includes mice achieve blood ethanol concentrations 
(BECs) of 80 mg/dl or greater and most notably, these BEC levels often exceed the NIAAA 
operational definition of a binge for humans, which is 80 ml/dl ≈0.08% BEC. Also, mice exhibit 
behavioral intoxication as measured by deficits in motor behavior in rotarod and balance beam 
tests (Rhodes et al., 2007). Moreover, excessive ethanol drinking associated with DID 
procedures does not appear to be driven by caloric need (Lyons et al., 2008). 
The neuroimmune system 
 In order to understand the potential roles that cytokines might play in ethanol 
consumption and sedation, it is important to have a basic understanding on how the 
neuroimmune system works and what functions the cytokines have when ethanol isn’t in the 
body. Innate immunity is the immune system’s first line of defense against invading organisms 
or pathogens coming into the body. Adaptive immunity, by contrast, involves the synthesis of 
antibodies to deal with specific viruses or other threats that escape the innate immune system’s 
defenses. Unless the body was previously exposed to these pathogens with subsequent antibodies 
circulating, the adaptive immune response may take a while to respond effectively to bodily 
threats. Thus, the innate immune system is always active while the adaptive system is usually 
silent unless activated (Sompayrac, 2008). Because of the innate immune system’s ever-present 
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activity, these immune components are found to be the most relevant focus for studies in 
communications or signaling between the nervous and the immune (or neuroimmune) systems. 
Macrophages are the immune system’s sentinels which have the job of monitoring the body for 
threats to the neuroimmune system. These macrophages have special pattern recognition 
receptors called toll-like receptors that recognize specific types of immune threats. Microglia are 
specialized macrophages that operate in the central nervous system. These microglia or glial 
astrocyte cells generate messenger molecules called cytokines to communicate with other cells. 
Some of the cytokines generated include interleukin-1 (IL-1), IL-6, IL-10, and Tumor necrosis 
factor –alpha (TNF-α). Notably, IL-1 expression can trigger IL-6 and TNF-α expression, and the 
over-expression of these cytokines can lead to the anti-inflammatory cytokine, IL-10, which acts 
to regulate these other cytokines (Sompayrac, 2008; Shastri, Bonifati, & Kishore, 2013). 
Generally, these immune processes can have either protective or pathogenic effects 
depending on the circumstances and duration of their expression. Indeed, if stress or a biological 
infection is great enough, neurons can recruit or generate immune elements to respond to these 
challenges. In fact, some immune components can also contain receptors for neurotransmitters 
(e.g., norepinephrine, epinephrine, & acetylcholine) and neuropeptides (e.g., neuropeptide Y 
[NPY], corticotropin releasing factor [CRF], & α-melanocyte-stimulating hormone [α-MSH]). In 
fact, NPY’s actions on macrophages have been found to reduce IL-6 expression. Depending on 
these biological circumstances, immune elements can either be neuroprotective or can destroy 
dysfunctional/biologically compromised neurons. (Walsh, Muruve, & Power, 2014; Sternberg, 
2006).  
The central nervous system can react to homeostatic challenges through local, regional, 
or systemic actions which may also include hormonal routes. The hypothalamic-pituitary-adrenal 
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(HPA) axis is a group of glands or structures that work together to regulate stress, 
neuroendocrine, and digestion processes but can also mediate and interact with innate immune 
components (Sternberg, 2006). The Vagus nerve is a nerve that acts as a communication relay 
between the heart, digestive tract, and the medulla oblongata in the brain. This bidirectional 
nerve can relay several types of signals such as hunger or satiety, but can also relay immune 
signals between the central nervous and the peripheral immune system (Rosas-Ballina et al, 
2015; Sternberg, 2006).  
The blood-brain-barrier is a tight junction (400 dalton or less permeability) of endothelial 
cells that regulate communication between the central nervous system (CNS) and the peripheral 
immune system. This barrier may allow some cytokines to signal, or be transported through these 
structures, but it generally protects the CNS from pathogens that the peripheral immune system 
might be fighting against (Banks, 2015). However, Alfonso-Loeches and others (2015) have 
reported that chronic exposure to ethanol may compromise the ability of the blood-brain-barrier 
to protect the brain from neuroinflammation, as demonstrated by greater expression of 
inflammatory genes in the cultured microglia of ethanol treated mice. This compromised barrier 
may be due to peripheral liver inflammation. The liver acts as a barricade between the gut and 
the rest of the body, and when there is significant inflammation, resident immune cells such as 
Kupffer cells generate or influence an immune response which can include cytokines and 
monocytes that can potentially force pass this barrier (D’Mello, & Swain, 2014; Rubio-Araiz et 
al., 2016). 
Additionally, there are small brain regions that do that have blood-brain-barrier 
protection and thus greater permeability which are classified as circumventricular organs. 
Several of these organs have connections to the hypothalamus in the brain (Banks, 2016). The 
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hypothalamus is one brain region that can generate a strong central cytokine response to 
peripheral immune challenges. In fact, IL-6 is the primary cytokine responsible for modulating 
inflammation and fever symptoms (Murta, Farias, Pitossi, & Ferrari, 2015). The amygdala is 
another brain region that has a prominent central immune presence. The amygdala is considered 
the hub or coordinator for receiving and integrating peripheral immune signals (Engler et al., 
2011.) Finally, Louveau and colleagues (2015) recently discovered lymphatic vessels that have 
been found in the central nervous system which allow transport of fluids and immune cells from 
the cerebrospinal fluid and the lymph nodes into the brain. However, the implications of this new 
discovery on a potential neuroimmune communication pathway have yet to be determined.  
The critical roles of interleukin 6 in the central nervous system 
 Interleukin-6 plays a variety of roles in the body such as regulating inflammation, 
contributing to neurogenesis, as well as endocrine roles. This cytokine may be produced by 
neurons, microglia, astrocytes, or endothelial cells. IL-6 (22-28 kilodalton) may bind to a 
membrane bound receptor (IL-6R, gp80, 80 kilodalton α-type receptor) or to a soluble receptor 
(sIL-6Rα). IL-6R is expressed in limited amounts, while sIL-6R is ubiquitous or pervasive. 
Regardless of which receptor IL-6 binds to, IL-6 needs the ubiquitous protein gp130 (130 
kilodalton β-type receptor) for signaling (Erta, Quintana, & Hidalgo, 2012; Hunter, & Jones, 
2015). The IL-6 receptor is synthesized in the endoplasmic reticulum and will appear 45 minutes 
after synthesis at the cell surface. Notably, the half-life of IL-6R and gp130 is approximately 2-3 
hours. However, an increased presence of IL-6 will not escalate the rate of IL-6R or gp130 
degradation due to the diverse cell type mechanisms that process IL-6 (Gerhartz et al, 1994).  
IL-6 is a critical cytokine that controls the transition from innate to adaptive immune 
processing. However, the roles of IL-6 may be heavily context dependent (Erta, Quintana, & 
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Hidalgo, 2012). IL-6’s role may depend on the level of inflammation in the affected regions. IL-
6, in concert with sIL-6Rα has been found to modulate the transition between acute and chronic 
inflammation. IL-6 has been suggested to be protective in low levels, but to be proinflammatory 
during chronic inflammation. One way that IL-6 has been found to be protective is by inducing 
production of the anti-inflammatory interleukin-1 receptor antagonist (Gabay, 2006). It would 
seem by most accounts that IL-6’s main goal is to maintain homeostasis in the body. Yet, how 
might one understand how IL-6 might be able to potentially have different seemingly 
contradictory roles in the body? 
Interleukin-6 has three signaling pathways that it is known to act on within the body. The 
least relevant pathway to the topic of neuroimmune signaling is the role that IL-6 plays in the 
skeletal muscle system. In this system, IL-6 is produced as a myokine which is essentially a 
cytokine secreted by muscles. In this capacity, IL-6’s primarily role appears to be to reduce 
inflammation and enhance functionality within the muscles, as well as enter the blood stream and 
impact the body’s metabolism. This, in turn, can have an impact on body mass and is presently 
investigated in obesity research. As a myokine, IL-6 follows a different pathway of signaling and 
expression than as the cytokine IL-6 (Pal, Febbraio, & Whitham, 2014; Guijarro, Laviano, & 
Meguid, 2006).  
The two most relevant pathways that IL-6 acts on within the neuroimmune system are the 
classic signaling and the trans-signaling pathways. Classical signaling is when IL-6 binds to IL-
6R and gp130. Classical signaling helps maintain homeostasis and can be neuroprotective. 
Trans-signaling is when IL-6 binds with sIL-6R and gp130. Trans-signaling is largely 
responsible for chronic inflammation (and depression) since the pervasiveness of these binding 
elements allow IL-6 to affect cells that do not express IL-6R. Trans-signaling has been suggested 
 7 
 
to be involved in gut permeability, which is one of the proposed ways that binge ethanol 
exposure has been proposed to cause cytokines to circulate and impact the neuroimmune system. 
Soluble gp130 is one of the endogenous antagonists to this trans-signaling. This antagonist works 
by competing with the gp130 protein for binding to the IL-6 complex (Maes, Anderson, Kubera, 
& Berk, 2014; Jostock et al., 2001).  
In neurons, IL-6 can act as a neuromodulator. For example, Hernandez and colleagues 
(2016) recently reported that transgenic mice that were engineered to generate increased 
astrocytic induced IL-6 expression demonstrated altered synaptic function from acute ethanol 
exposure.  IL-6 has been found in the PVN and other regions of the hypothalamus, the 
hippocampus, and also the cerebellum. Within these structures, the majority of IL-6 mRNA 
expression was found in neurons (Benrick, et al., 2009; Sallmann, et al., 2000; Aniszewska et al., 
2015; Jankord et al., 2010).  IL-6 has been detected in both cholinergic and GABAergic neurons. 
IL-6 is considered a neuropoietic cytokine because it promotes neuronal survival. Depending on 
the concentrations of IL-6, this cytokine can protect against NMDA excitotoxicity, which is a 
factor in chronic alcohol drinking. IL-6 may influence neurons directly, but may also act as a 
messenger between glia and neurons (Juttler, Tarabin, & Schwaninger, 2002). In fact, some 
preliminary research suggests that IL-6 may act pre-synaptically or post-synaptically to alter 
neurotransmitter release (Gruol, 2015; Crowley, Cryan, Downer, & O’Leary, 2016). Yet, this 
aforementioned type of neuronal meditated IL-6 signaling would most likely be considered 
classical signaling since inflammation does not appear to be the endpoint.  
The different roles of cytokines in ethanol consumption 
There are several cytokines that have been implicated in ethanol consumption behaviors 
such as IL-1, IL-6, IL-10, TNF-α, and MCP-1. These cytokines have different roles in the brain 
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based upon the levels of ethanol exposure.  Alcohol exposures have been found to act on the toll-
like receptors TLR4 and IL-1R (Fernandez-Lizarbe, Pascual, Gascon, Blanco, & Guerri, 2008). 
Toll-like receptors then produce cytokines. IL-1 has been found to induce IL-6 and TNF-α. The 
anti-inflammatory cytokine IL-10 is later synthesized to counter the proinflammatory cytokines 
IL-1, IL-6 and TNF-α. Ethanol has been linked to the production of TNF-α, MCP-1, IL-6, and 
IL-1, and the use of cytokine neutralizing antibodies blunt cytokine expression and attenuates 
ethanol sensitization to glutamate neurotoxicity (Emanuele et al., 2005; Zou, & Crews, 2010).  
Pro-inflammatory interleukin 1(β) has been demonstrated to have an increased expression 
within the neurons and astrocytes of the hippocampi of postmortem alcoholic brains (Zou & 
Crews, 2012). Genetic polymorphisms of IL-1β have been found with several alcohol dependent 
patients, in comparison with non-dependent healthy controls (Liu, Hutchinson, White, Somogyi, 
& Coller, 2009). Genomic microarrays have also identified IL-6 signaling as a contributor gene 
to alcohol preference (Mulligan et al., 2006). Kane and colleagues (2014) report ethanol-induced 
increases of pro-inflammatory IL-6 mRNA in the cerebellum of C57BL/6J mice in response to 
oral gavage of 6 g/kg ethanol. Also, within the same study pro-inflammatory MCP-1 mRNA 
levels were increased within the hippocampus, cerebellum, and cerebral cortices of these mice. 
In support of the ethanol-induced IL-6 changes, two other studies found ethanol applied to 
astroglia or microglia in culture caused an increase in IL-6 expression (Boyadjieva, & Sarkar, 
2010; Sarc, Wraber, & Lipnik-Stangelj, 2010). In another postmortem study of alcoholic brains, 
high concentrations of MCP-1 were found in the VTA and the amygdala (He & Crews, 2008).  
 Marshall and colleagues (2013) exposed rats to a binge ethanol paradigm, and 
discovered increased expression of anti-inflammatory IL-10 seven days after the ethanol 
exposure. Qin and colleagues (2008) report increased pro-inflammatory TNF-α expression in 
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whole brain assessments of C57BL/6J mice after being exposed to oral gavage of 5 g/kg ethanol. 
Also, Emanuele and colleagues (2005) exposed rats to a chronic ethanol paradigm which 
increased TNF-α and IL-6 expression in their hypothalamus(i). Additionally, alcohol dependent 
patients admitted to a hospital show the highest TNF-α serum levels and liver 
dysfunction/disease as compared to moderate, light, and abstaining alcohol drinkers. 
Furthermore, the TNF gene polymorphism of the -238A allele has been associated with a high 
prevalence for liver disease (Gonzalez et al., 2008). In fact, the liver contains Kupffer cells 
which synthesize TNF-α and other cytokines. TNF-α passed into serum can induce MCP-1 and 
TNF-α in the brain, such that TNF-α can remain in the brain for at least 10 months and cause 
neurodegeneration (Crews et al., 2006). TNF-α is a particularly dangerous cytokine that has been 
associated with neuronal death, specifically in dopamine cells (Shastri, Bonifati, & Kishore, 
2013). Thus, it could be argued that IL-1 induces other cytokines, (e.g. IL-6), with TNF-α and 
MCP-1 being some of the cytokines present before neuronal death. 
However, one of the strongest examples of the role of central immune gene expression in 
the modulation of ethanol consumption is found in a study by Liu and colleagues (2011). In this 
study, the research group utilized RNA silencing technologies (siRNA) to selectively knock out 
TLR4 in the central amygdala of alcohol preferring rats. This TLR4 knockdown reduced operant 
responding for ethanol, but not responding for the more palatable sucrose. Thus, within this 
study the central immune response was altered or blocked, which in turn reduced alcohol 
consumption. Other examples include mice with the Knock-Out (KO) of IL-1 and IL-6 genes 
showing reduced ethanol consumption within two bottle alcohol preference tests (Blednov et al., 
2012).  
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The cytokine contribution to alcohol dependence: A potential model of cytokine actions 
In consideration of the cytokine roles in the brain in response to normal and/or ethanol 
modulated processes, there is the implication that pro-inflammatory cytokine expression 
increases binge-like ethanol drinking. One model that has been postulated to account for the 
actions of the central cytokines within the pathway to dependence or addiction is the Allostasis 
model developed by Dr. George Koob. Homeostasis is characterized by the bodily processes that 
work to maintain the functionality and survival of an organism. Allostasis refers to the process 
where the same adaptive processes that work within homeostasis become dysregulated and these 
adaptive processes change to attain stability, yet these changes push the regulatory systems 
outside the normal set-point into a potentially pathological set-point (Koob, 2003; Koob & Le 
Moal, 2001). Potentially the impairment in the homeostatic role of IL-6 might be responsible for 
the inability of the homeostatic mechanisms to attain the original normal set-points. 
The descent into alcohol addiction is characterized by experiences of positive and 
negative reinforcement. At first, alcohol activates the brain reward systems and generates a 
pleasurable experience. This period of positive reinforcement causes the alcohol user to binge 
drink alcohol in pursuit of the initial pleasures of alcohol use. Yet, as the body adapts to the 
continued binge exposures of alcohol, the body does not respond in the same ways to this drug. 
After several binge exposures to alcohol, cessation of alcohol drinking (abstinence) causes the 
aversive withdrawal state. In this period of negative reinforcement, alcohol is then taken to 
reduce the aversive effects of the withdrawal experience (i.e., relapse). Binge cycles of alcohol 
use and withdrawal alter the normal set-points into an allostatic state. While in the allostatic 
cycle, prior set-points are no longer attainable. Thus, the perpetual cycles eventually descend into 
a pathological state (Koob & Le Moal, 2001; Koob, 2003). These cycles are easily represented 
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by multiple binge-like cycles of DID in mice. Mice are expected to demonstrate similar 
behaviors to humans in response to this extended binge-like alcohol exposure. 
The reward circuitry involved with alcohol reinforcement includes the extended 
amygdala (including the BNST), the lateral hypothalamus, the nucleus accumbens, and the 
ventral tegmentum area (VTA) (Koob, 2003).  These same brain areas (with the exception of the 
VTA) have been found to host interactions between the neurotransmitters (serotonin and 
dopamine) implicated in the alcohol allostasis model and the cytokines IL-1(β), IL-6, and TNF-α 
(Brebner, Hayley, Zacharko, Merali, & Anisman, 2000).  Additionally, the central amygdala was 
found to host interactions between TNF-α and GABA (Knapp et al, 2011). Furthermore, the 
innate immune response to pathogens has been found to have interactions with the opioids, 
glucocorticoids, NPY, and CRF throughout the central nervous system (Sternberg, 2006). Thus, 
it could be argued that cytokines (such as the homeostatic IL-6) interact with key 
neurotransmitters and neuropeptides in regions implicated in alcohol reinforcement processes. 
While the framework for the allostatic model is not complete, given the cited evidence, it seems 
likely that cytokines contribute vitally to alcohol dependence/pathology. 
 Potential role of the pro-inflammatory cytokines in the relation between sensitivity to 
ethanol-induced sedation and ethanol intake 
 
Work by Dr. Mark Shuckit (1994) has demonstrated that a low level of response or 
sensitivity to ethanol, as evident by delayed intoxication or sedation, has been associated with 
high risk for later alcoholism. Furthermore, children of alcoholics will also show a higher risk for 
alcoholism, when compared to children from a non-alcoholic lineage. Shuckit and colleagues 
(2011) suggest that the low sensitivity to ethanol may be seen as both a genetic and 
environmental contributor to alcoholism. The genetic component lies in the fact that 
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approximately 50% of low alcohol response is genetically mediated. The environmental 
component is due to the higher number of drinks needed to achieve the desired ethanol effects. 
Paralleling these facts, cytokines have been demonstrated to produce an environmental factor in 
ethanol drinking, (as previously stated), and cytokine gene polymorphisms have been implicated 
with higher incidences of alcohol dependence (Liu et al., 2009; Gonzalez et al., 2008). Thus, pro-
inflammatory cytokines may play a role in ethanol sensitivity.    
Ethanol drinking has been shown to increase pro-inflammatory cytokine expression, and 
cytokine expression increases ethanol drinking. Based upon a review of the literature, it would 
seem that pro-inflammatory cytokines have an antagonistic relation with ethanol 
sensitivity/sedation. Thus, pro-inflammatory cytokines would be expected to lower sensitivity to 
sedation, and would increase ethanol consumption. Sedation may be motivated by an energy 
metabolism factor, and may actually work to stop a potential cytokine induced illness. Indeed, 
cytokine antagonists may increase ethanol-induced sedation.  
However, it is also possible the cytokines may generate a high sensitivity/sedation due to a 
potential over-response of cytokines which would then usher in sickness or sedation to cope with 
the cytokine response. In this scenario, cytokine antagonists would work to normalize the 
cytokine over-reaction. Wu and colleagues (2011) report that the high peripheral dose of 100 
mg/kg/i.p. IL-1RA reduced ethanol-induced sedation (sleep time) and motor impairment. 
Additionally, this research team (2011) also reports that TLR4 KOs and Myd88 KOs (immune 
gene knock-out mice) show reduced sedation and motor impairment than matched controls. 
Corrigan and colleagues (2014) also report that TLR2 KOs show minimal sedation behaviors in 
comparison to wild-type controls. Yet, high doses of antagonist or gene deletion may not present 
that best tools for assessing IL-1’s actions. Gene knockdown methods are preferable tools to 
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avoid developmental or immune system defects, or compensations from never possessing the 
gene (KO mice). Also, gene knockdown methods allow temporal and spatial characterization or 
manipulation of these genes that is not easily achieved with KO mice or peripheral injections. In 
contrast to the previously referenced studies, Vicente-Rodriguez and colleagues (2014) report 
that mutant mice that overexpress the cytokine pleiotrophin show enhanced ethanol preference 
and reduced sedation/ataxia in response to ethanol administration. As evident by these 
aforementioned studies, prior research has provided mixed results concerning the role of 
cytokines in ethanol sensitivity and sedation. However, the anticipated result for these studies, 
based upon prominent alcoholism theories, is for pro-inflammatory cytokines to lower sensitivity 
to sedation, and increase ethanol consumption. 
Goals of Current Dissertation 
The overarching goal of this dissertation is to examine the roles of proinflammatory 
cytokines, specifically IL-6, in binge-like ethanol consumption and ethanol-induced sedation. 
The experiments of chapter 2 characterize the expression of IL-6 in the central amygdala, 
paraventricular nucleus of the hypothalamus (PVN), and other candidate regions of the brain in 
response to binge-like ethanol consumption. Within these experiments, mice were exposed to 1 
or 3 cycles of binge-like drinking cycles through use of the “Drinking in the Dark” (DID) 
protocol consisting of either 20% v/v ethanol or water.  Following the DID protocol, mice brains 
were analyzed through immunohistochemical procedures examining IL-6 immunoreactivity in 
candidate regions of the brain implicated in the neurobiological responses to ethanol. In chapter 
3, experiments were performed with site-directed infusions of IL-6 receptor antagonist to alter 
proinflammatory cytokine signaling and determine the critical regions in which IL-6 modulates 
binge-like ethanol consumption. These IL-6 receptor antagonists were site-specifically 
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administered on the test day of the DID protocol with ethanol.  Following up on these findings 
were sucrose DID tests that were used to determine that consumption in general was not reduced, 
or that taste perception was not altered by the application of this cytokine antagonist. Chapter 4 
describes the experiments that were run to assess whether IL-6 specifically modulated ethanol’s 
sedative/ataxic properties, through the use of site-directed infusions of IL-6 receptor antagonist 
employed to alter proinflammatory cytokine signaling in the central amygdala. Mice were 
exposed to an intraperitoneal ethanol administration followed by the application of the IL-6 
receptor antagonist. Subsequent to this protocol, mice were tested on their motor reflexes with a 
rotarod apparatus to determine the antagonist’s impact on ethanol-induced sedation.  
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Chapter 2 
Binge-like ethanol consumption effects on central interleukin-6 expression 
Introduction 
A growing body of evidence suggests that central cytokines play critical roles of 
modulating neurobiological responses to ethanol. IL-6 is one of the noteworthy cytokines that 
have been previously implicated in alcohol consumption. For example, ethanol has been linked 
to the production of the cytokines: TNF-α, MCP-1, IL-6, and IL-1 (Emanuele et al., 2005; Zou, 
& Crews, 2010). Kane and colleagues (2014) report ethanol-induced increases of pro-
inflammatory IL-6 mRNA in the cerebellum of C57BL/6J mice in response to oral gavage of 6 
g/kg ethanol. Emanuele and colleagues (2005) exposed rats to a chronic ethanol paradigm which 
increased TNF-α and IL-6 expression in their hypothalamus.  In support of the ethanol induced 
IL-6 changes, two other studies found ethanol applied to astroglia or microglia in culture caused 
an increase in IL-6 expression (Boyadjieva, & Sarkar, 2010; Sarc, Wraber, & Lipnik-Stangelj, 
2010). Genomic microarrays identified IL-6 as a contributor gene to alcohol preference 
(Mulligan et al., 2006). Finally, deletion of IL-1 and IL-6 genes resulted in reduced ethanol 
consumption within 2-bottle preference tests (Blednov et al, 2011).  
The present study examined the role of brain IL-6 in excessive binge-like ethanol 
drinking in C57BL/6J mice, by assessing IL-6 immunoreactivity in key brain regions previously 
implicated in modulating neurobiological responses to ethanol.  Mice were exposed to a 4 day 
“drinking in the dark” (DID) binge-like ethanol consumption procedure, which promotes high 
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ethanol intakes with associate blood ethanol concentrations in excess of 80 mg/dl (Sparta et al., 
2008; Lowery et al., 2010). 
Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were used in all 
experiments. Mice were approximately 6-8 weeks old and weighed between 20-25g at the 
beginning of experimental procedures. Mice were individually housed in polypropylene cages 
with corncob bedding and ad libitum access to standard rodent chow (Purina RMH 3000, 
Tekland, Madison, WI) and water, except where noted in experimental procedures. The colony 
rooms were maintained at 22ºC with a reverse 12-hr/12-hr light/dark cycle with lights out at 10 
a.m. Mice were run in two cohorts for this study. Cohort 1 consisted of 30 mice used in water 
and sucrose intake experiments. Cohort 2 consisted of 30 mice used in water and ethanol intake 
experiments. All experimental procedures were approved by the University of North Carolina 
Institutional Animal Care and Use Committee (IACUC) and complied with the NIH Guide for 
Care and Use of Laboratory Animals (National Research Council, 1996). 
Binge-Like Drinking Procedures 
The “drinking in the dark” (DID) protocol involves a 4-day procedure and is an animal 
model of binge ethanol consumption (Rhodes et al., 2005). Throughout the present experiments, 
mice remain in their home-cages in the vivarium. Beginning 3 hours into the dark cycle, water 
bottles were removed from the home-cage and replaced with a bottle containing a solution of 
20% (v/v) ethanol. On days 1-3, ethanol bottles remained on the cages for 2 hours before 
removal and replacement with water bottles. On day 4 (the test day), procedures were the same 
as on days 1-3 except mice had access to ethanol for 4 hours. Mice were exposed to 1 or 3 cycles 
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(weeks) of the DID protocol with ethanol, or 3% sucrose in a separate experiment. Control 
groups underwent 3 cycles of the DID protocol with water. Mice were euthanized via ketamine 
(10mg/kg) /xylazine (100mg/kg) overdose and transcardially perfused with 0.1M phosphate 
buffered saline followed by 4% paraformaldehyde at the end of the DID period. Brains were 
extracted and sectioned using a vibratome. Tail blood samples (10µl) were collected after Day 4 
Binge Test, though blood ethanol concentrations (BECs) could not be calculated due to 
equipment failure. Ethanol consumption is expressed as g/kg. Sucrose consumption is expressed 
as ml/kg. 
Immunohistochemistry Procedures  
Free floating sections were rinsed in phosphate buffered saline (PBS) and endogenous 
peroxidases quenched with 0.6% H2O2 in PBS. Following additional washes and a blocking step 
(PBS/ 0.1% of triton-X / 3% goat serum; Vector Laboratories, Burlingame, CA), sections were 
incubated in rabbit IL-6 (1:2000, Abbiotec, San Diego, CA) primary antibody for 72 hours at 
4˚C.  Primary antibody was washed away using the blocking solution, and sections were then 
incubated in biotinylated  goat anti-rabbit secondary antibody and detected with avidin-biotin-
peroxidase complex (ABC elite kit, Vector Labs) with the chromagen, 3,3’-diaminobenzidine 
tetrahydrochloride (Polysciences; Warrington, PA). Sections were mounted and coverslipped 
with SHUR/Mount™ (Triangle Biomedical Sciences; Durham, NC).  Images were taken of the 
entire slide at 100x magnification with a Zeiss Axio Zoom V16 microscope (Zeiss; Jena, 
Germany). Slides were coded to ensure experimenter blindness to treatment conditions for 
quantification. Subregions of the amygdala or the hypothalamus were traced separately for each 
slide. IL-6 immunoreactivity was determined using ZenPro 2012. Immunopositive pixels were 
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determined by optical density with an experimenter determined threshold. Data points are 
expressed as percent area, which is pixels/area in micro meters. 
Data Analysis 
One-way and two-way analyses of variance (ANOVAs) were used to assess group 
differences in IL-6 IR as a function of binge-like ethanol consumption versus water intake or of 
binge-like sucrose consumption versus water intake. LSD post-hoc tests were used to determine 
specific differences in IR between the continuous water and all other groups. Significance was 
accepted at p<0.05; all data is presented as mean ± SEM. For IR data, some animals were 
excluded from analysis (due to brain region availability or outlier IR staining of greater than two 
standard deviations from the mean as determined by the “Grubbs test for outliers”), which 
accounts for differences in degrees of freedom between similar analyses. 
Results 
No significant differences in binge-like ethanol consumption or sucrose consumption 
Mice in the 1 week or 3 week DID procedure consumed similar amounts of 20% ethanol 
on day 4 during the Binge Test. On day 4, mice exposed to 1 or 3 weeks of the DID procedure 
consumed (5.22±0.24, 5.52±0.67g/kg, respectively; F(1,17)= 0.420, p=0.692), (Figure 2.1A). 
This level of consumption is associated with BECs of ~100mg/dl (Lowery-Gionta et al., 2012). 
Mice in the 1 week or 3 week DID procedure with 3% sucrose consumed similar amounts of 
sucrose (176.70±13.68, 188.1±10.68 ml/kg, respectively; F(1,9)= 0.403, p=0.541). Also, as 
would be expected, mice who had access to water only consumed significantly less fluid than the 
sucrose exposed mice (52.52±4.23, F(2,13)=45.58, p=0.0001). Fluid consumption (ml/kg) during 
a separate 1 or 3 week DID procedure with 3% sucrose or water (Figure 2.1B) 
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Multiple cycles of DID with ethanol are associated with increased IL-6 expression in the 
central amygdala (CEA)  
Mice were exposed to 1 or 3 weeks of DID with 20% ethanol, or 3 weeks of monitored 
water consumption within the primary IR experiment. In a separate experiment, mice were 
exposed to 3 weeks of DID with 3% sucrose, or with 3 weeks of monitored water consumption. 
Mice exposed to DID with ethanol demonstrated significantly greater IL-6 IR in the CEA than 
mice exposed to 3 weeks of water (F(2,24)=3.481, p=.047). This effect was primarily driven by 
mice exposed to 3 weeks of DID with 20% ethanol (p=.014) and not mice exposed to 1 week of 
DID (p=.121), versus water controls (Figure 2.2A). Notably, there were no significant 
differences between the 1 or 3 week DID ethanol groups and water controls with IL-6 IR in the 
BLA (F(2,24)= .939, p=.405) (Figure 2.2B). In the separate experiment, mice exposed to 3 
weeks of DID with sucrose demonstrated no significant differences with IL-6 IR in the CEA than 
mice exposed to 3 weeks of water (F(1,6)=0.024, p=.882). Grubbs test for outliers found two 
outliers that were subsequently removed from data analysis: One mouse had a score of 25.05 in 
the sucrose group, and another mouse had a score of 29.86 in the water group. (Figure 2.2C). All 
data points are expressed as percent area, which is pixels/area in micro meters. Representative 
photomicrographs of IL-6 IR in the BLA and CEA are shown at 100X (Figure 2.3).  
Multiple cycles of DID with ethanol are associated with increased IL-6 expression in the 
paraventricular nucleus of the hypothalamus (PVN).  
Mice were exposed to 1 or 3 weeks of DID with 20% ethanol, or 3 weeks of monitored 
water consumption within the primary IR experiment. In a separate experiment, mice were 
exposed to 1 or 3 weeks of DID with 3% sucrose, or with 3 weeks of monitored water 
consumption. Mice exposed to DID with ethanol demonstrated significantly greater IL-6 IR in 
the PVN than mice exposed to 3 weeks of water (F(2,23)=4.237, p=.027).This effect was 
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primarily driven by mice exposed to 3 weeks of DID with 20% ethanol (p=.008) and not mice 
exposed to 1 week of DID (p=.258), versus water controls (Figure 2.4A). In the separate 
experiment, mice exposed to 1 or 3 weeks of DID with sucrose showed no significant differences 
in IL-6 IR in the PVN than mice exposed to 3 weeks of water (F(2,12)=2.006, p=.177)¸ 
suggesting an ethanol specific effect on IL-6 expression at both 1 and 3 weeks of DID exposure 
(Figure 2.4B). Additionally, there were no significant differences between the 1 or 3 week DID 
ethanol groups and water controls with IL-6 IR in adjacent regions of the hypothalamus, such as 
the arcuate nucleus (F(2,21)=1.504, p=.245). All data points are expressed as percent area, which 
is pixels/area in micro meters. Representative photomicrographs of IL-6 IR in the PVN are 
shown at 100X (Figure 2.5) 
Multiple cycles of DID with ethanol did not alter IL-6 expression in the lateral septum, 
nucleus accumbens, or bed nucleus of the stria terminalis (BNST).  
Mice were exposed to 1 or 3 weeks of DID with 20% ethanol, or 3 weeks of monitored 
water consumption within the primary IR experiment. There were no significant differences 
between the 1 or 3 week DID ethanol groups and water controls with IL-6 IR in the dorsal, 
intermediate, or ventral lateral septum (F(2,24)= .450, p=.643;  F(2,25)=.586, p=.564;  F(2,25)= 
.115, p=.892;  respectively). There were no significant differences between the 1 or 3 week DID 
ethanol groups and water controls with IL-6 IR in the nucleus accumbens core or shell 
(F(2,23)=.343, p=.713;  F(2,23)=1.587, p=.226;  respectively). There were no significant 
differences between the 1 or 3 week DID ethanol groups and water controls with IL-6 IR in the 
BNST (F(2,24)= .010, p=.990). These regions were chosen based upon the roles that they play 
with reward processes, and these non-significant results suggest an ethanol consumption 
mediated circuit involving IL-6 in both the CEA and the PVN, without the contributions of the 
lateral septum, nucleus accumbens, or BNST. 
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Discussion 
Relative to water drinking controls, IL-6 immunoreactivity (IR) is up-regulated in the central 
amygdala and the paraventricular nucleus of the (PVN) hypothalamus of mice with a history of 
three binge-like ethanol drinking cycles. This effect is not found in mice that were only exposed 
to one binge-like ethanol drinking cycle. In a separate study comparing sucrose versus water 
drinking induced IL-6 IR, no significant differences with IL-6 IR were found in the central 
amygdala or the PVN. This sucrose consumption finding suggests that IL-6 has unique actions in 
response to ethanol consumption, which are not found with consumption of other salient 
reinforcers. Additionally, IL-6 IR is unaffected in the (adjacently located) basolateral amygdala 
of mice with a history of three binge-like ethanol drinking cycles. Notably, IL-6 IR is not 
increased in the BNST or the nucleus accumbens in response to one or three cycles of binge-like 
ethanol drinking. This seems to indicate that IL-6 does not have a direct effect on the regions of 
the reward circuitry indicated in Koob’s (2003) allostatic model of alcohol addiction. Also, IL-6 
IR is not increased in the lateral septum in response to one or three cycles of binge-like ethanol 
drinking. The lateral septum is a non-classical reward related region of interest that has been 
regarded as important for ethanol consumption as described by Ryabinin, Bachtell, and 
colleagues (2003, 2003, & 2008). Additionally, Breese and colleagues (1984) described the 
septum as a region that is important for mediating ethanol induced motor impairment or sedative 
behaviors. However, the significant effects in the central amygdala and the PVN suggest that 
increased IL-6 expression in the brain is site-specific in response to alcohol consumption. The 
fact that three cycles or weeks of ethanol exposure, and not one week of ethanol exposure, are 
needed to produce the enhanced IL-6 expression over the water controls suggests that IL-6 
actions are more relevant in subjects with an extended history of binge-like ethanol consumption. 
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While the BECs were not able to be analyzed due to equipment failure, the high level of ethanol 
consumption found with these experimental animals is associated with BECs of ~100 mg/dl 
found in previous studies (Lowery et al., 2012). 
The fact that enhanced IL-6 expression was found in the PVN and the CEA is especially 
significant since the importance of these structures has been previously demonstrated in prior 
ethanol consumption studies. For example, neuropeptide Y signaling in the PVN and the CEA 
has been found to critically modulate ethanol consumption (Sparrow et al., 2012; Kelley et al., 
2001). Also, the neuropeptide corticotrophin releasing factor (CRF) which has been found to be 
greatly expressed in the PVN and the CEA, has also been found to critically modulate ethanol 
consumption (Wills, Knapp, Overstreet, & Breese, 2010). 
Prior immune studies offer a different view of the role of IL-6 in the CEA and the PVN. 
The central amygdala is commonly viewed as one the brain regions responsible for processing 
peripheral immune signals to the brain. In fact, Engler and colleagues (2011) reported that an 
intraperitoneal injection of bacterial lipopolysaccharide (LPS) induced pronounced IL-6 
expression in the central amygdala, with slightly lesser expression in the basolateral amygdala. 
In terms of the PVN, most of the prior IL-6 studies focused on the hypothalamus in general and 
not on the PVN specifically. Kakizaki and colleagues (1999) reported that LPS administration 
increased IL-6 expression in the PVN. Vallieres and Rivest (1999) also report that mice that were 
pretreated with LPS and later treated with IL-6 demonstrated enhanced CRF expression in the 
PVN. Benrick and colleagues (2009) reported that IL6 KO mice showed diminished expression 
of CRF in the PVN, and that IL-6Rα was co-expressed with CRF in the PVN. IL-6 in the 
hypothalamus was found to be increased due to exposure to a variety of stressors including 
footshocks, hypoxia, chronic unpredictable stress, and restraint (Jankord, et al., 2010; Girotti, et 
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al., 2013). In a separate study, the forced swimming stressor was found to increase IL-6Rα in the 
hypothalamus of stressed mice (Aniszewska, et al., 2015).  
In support of our findings of the ethanol induced IL-6 expression effects in the PVN and 
the CEA, a contemporary research group found similar findings with IL-6 mRNA in response to 
an extended ethanol administration paradigm. While these experiments were in their finishing 
stages in the Thiele/Lysle lab collaboration, Doremus-Fitzwater and colleagues (2014, 2015) 
reported in two separate studies that an extended regimen of intraperitoneal or intragastric doses 
of ethanol will induce enhanced IL-6 mRNA in the amygdala and the PVN. Notably, these 
results were determined by the use of an alternative technique known as reverse transcription 
polymerase chain reaction which reports mRNA expression, but does not allow precise spatial 
resolution to confirm that the expression of IL-6 is most likely due to central amygdala 
contribution and not due to adjacent regions of the amygdala, such as the basolateral amygdala. 
There are other notable differences between this group’s and our group’s findings. For example, 
intraperitoneal and intragastically applied ethanol represent forced ethanol exposure versus the 
greater face validity found with the voluntary consumption in our DID paradigm. Furthermore, 
our DID paradigm would have likely generated lower BECs due to the rodent’s propensity to 
limit consumption when its desired intoxication level is reached. Thus, our results would have 
been valid at an even lower ethanol exposure than the forced ethanol administration paradigms. 
Also, our immunochemistry experiments demonstrate the novel finding that IL-6 protein is also 
increased in response to repeated cycles of binge-like ethanol consumption. Despite technical 
differences, this contemporary research group’s findings support our research. Together, these 
results indicate that IL-6 signaling in the central amygdala (CEA) and the paraventricular 
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nucleus of the hypothalamus (PVN) may be involved in the progression or maintenance of binge-
like ethanol drinking.  
The following study, described in the next chapter, explored the role of IL-6 in binge-like 
ethanol drinking by antagonizing IL-6R in the CEA or the BLA during the third week of the DID 
procedure. IL-6R antagonism in the CEA or the BLA was also applied in the third week of the 
DID procedure with sucrose to establish the extent of IL-6R’s role in the consumption of an 
alternative salient reinforcer.  
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Figure 2.1 Ethanol, sucrose, and water consumption data. (A) Binge-like ethanol consumption 
(g/kg) during 2-hour access to 20% ethanol on days 1-3 of the DID procedure and during 4-hours 
of ethanol access on day 4 during the Binge Test. On day 4, mice exposed to 1 or 3 weeks of the 
DID procedure consumed ~5 g/kg of ethanol over the 4 hour test. This level of consumption is 
associated with BECs of ~100mg/dl (Lowery-Gionta et al., 2012). (B) Fluid consumption 
(ml/kg) during a separate 1 or 3 week DID procedure with 3% sucrose or water. All data are 
expressed as mean ± SEM.  
 
 
A 
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Figure 2.2 Multiple cycles of DID with ethanol are associated with increased IL-6 expression in 
the central amygdala (CEA). (A) Mice exposed to 3 weeks of DID with 20% ethanol showed a 
significant increase (p=.014) in IL-6 immunoreactivity in the CEA versus water controls. 
However, there were no significant differences in IL-6 immunoreactivity in the BLA (B). (C) 
Mice exposed to 3 weeks of DID with 3% sucrose showed no significant difference in IL-6 
immunoreactivity in the CEA versus water controls, suggesting an ethanol specific effect on IL-6 
expression at 3 weeks of DID exposure. All data points are expressed as percent area, which is 
pixels/area in micro meters, and as mean ± SEM. 
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Figure 2.3 Representative photographs of IL-6 immunoreactivity in the amygdala. (A) Mice 
exposed to 3 weeks of DID with 20% ethanol show a significant increase in IL-6 
immunoreactivity in the central amygdala (CEA) versus water controls (B). However, there were 
no significant differences in IL-6 immunoreactivity in the basolateral amygdala (BLA) (A/B). 
Representative photographs of IL-6 immunoreactivity are shown at 100X. 
  
A 
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Figure 2.4 Multiple cycles of DID with ethanol are associated with increased IL-6 expression in 
the paraventricular nucleus of the hypothalamus (PVN). (A) Mice exposed to 3 weeks of DID 
with 20% ethanol showed a significant increase (p=.008) in IL-6 immunoreactivity in the PVN 
versus water controls. However, there were no significant differences in IL-6 immunoreactivity 
in adjacent regions of the hypothalamus (data not shown). (B) Mice exposed to 1 or 3 weeks of 
DID with 3% sucrose showed no significant differences in PVN IL-6 immunoreactivity versus 
water controls, suggesting an ethanol specific effect on IL-6 expression at 3 weeks of DID 
exposure. All data points are expressed as percent area, which is pixels/area in micro meters, and 
as mean ± SEM. 
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Figure 2.5 Representative photographs of IL-6 immunoreactivity in the paraventricular nucleus 
of the hypothalamus (PVN). (A) Mice exposed to 3 weeks of DID with 20% ethanol show a 
significant increase in IL-6 immunoreactivity in the PVN versus water controls (B). 
Representative photographs of IL-6 immunoreactivity are shown at 100X. 
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Chapter 3 
Interleukin-6 receptor antagonism effects on binge-like ethanol consumption 
Introduction 
Binge ethanol drinking is a risky pattern of drinking that leads to several short and long 
term consequences, with the most prominent consequence being an increased risk of dependence 
(Courtney & Polich, 2009).  Indeed, there is an accumulation of evidence suggesting that 
repeated binges alter neurobiological systems to create a stronger motivation to consume ethanol, 
paralleling the enhanced ethanol consumption and overlapping with the neurobiological changes 
found in dependence-induced drinking (Sprow, & Thiele, 2012). The neuroimmune system with 
its associate cytokine actions have been implicated in the neurobiological changes resulting from 
abusive ethanol consumption. IL-6 is one of the notable cytokines that have been previously 
implicated in alcohol consumption. For example, genomic microarrays identified IL-6 as a 
contributor gene to alcohol preference (Mulligan et al., 2006). Deletion of IL-1 and IL-6 genes 
resulted in reduced ethanol consumption within 2-bottle preference tests (Blednov et al, 2011). In 
support of ethanol induced IL-6 changes, two studies found ethanol applied to astroglia or 
microglia in culture caused an increase in IL-6 expression (Boyadjieva, & Sarkar, 2010; Sarc, 
Wraber, & Lipnik-Stangelj, 2010). Kane and colleagues (2014) report ethanol-induced increases 
of pro-inflammatory IL-6 mRNA in the cerebellum of C57BL/6J mice in response to oral gavage 
of 6 g/kg ethanol. Emanuele and colleagues (2005) exposed rats to a chronic ethanol paradigm 
 34 
 
which increased TNF-α and IL-6 expression in their hypothalamus. However, these previous 
studies did not report precisely where the site of action is for IL-6. The sites of action for ethanol 
induced IL-6 were explored in chapter two of this dissertation, and role of IL-6 in binge-like 
ethanol drinking is explored further within this chapter (3).   
The experiments described within chapter two expand on the role of interleukin-6 by 
demonstrating that IL-6 immunoreactivity (IR) is up-regulated in the central amygdala and the 
paraventricular nucleus of the (PVN) hypothalamus of mice with a history of three binge-like 
ethanol drinking cycles, but not in mice with a comparable history composed of three cycles of 
sucrose drinking. Notably, this effect was not found in mice that were only exposed to one binge-
like ethanol drinking cycle, which suggests IL-6 involvement is more critical after a history of 
binge-like drinking and could potentially mean that IL-6 might be mediating the neurobiological 
changes occurring in the overlap between binge-like ethanol drinking and dependence-induced 
drinking.  
Few studies have implicated a role for the PVN of the hypothalamus in binge-like ethanol 
drinking, but several studies have suggested a role for the central amygdala in binge-like ethanol 
drinking (Lowery-Gionta et al., 2012; Sparrow et al., 2012). Thus, in pursuit of the more 
promising target, the present study examined the role of brain IL-6 in excessive binge-like 
ethanol drinking in C57BL/6J mice, by antagonizing IL-6 receptor actions in key amygdalar 
brain regions previously implicated in modulating neurobiological responses to ethanol.  Mice 
were exposed to 3 weeks or cycles of the 4 day “drinking in the dark” (DID) binge-like 
consumption procedure, with 20% ethanol or 3% sucrose in separate experiments. 
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Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were used in all 
experiments. Mice were approximately 6-8 weeks old and weighed between 20-25g at the 
beginning of experimental procedures. Mice were individually housed in polypropylene cages 
with corncob bedding and ad libitum access to standard rodent chow (Purina RMH 3000, 
Tekland, Madison, WI) and water, except where noted in experimental procedures. The colony 
rooms were maintained at 22ºC with a reverse 12-hr/12-hr light/dark cycle with lights out at 10 
a.m. Mice were run in three cohorts for this study. Cohort 1 consisted of 24 mice used to explore 
CEA IL-6R antagonism’s effects on binge-like ethanol consumption. Cohort 2 consisted of 24 
mice used to explore CEA IL-6R antagonism’s effects on sucrose consumption. Cohort 3 
consisted of 24 mice used to explore BLA IL-6R antagonism’s effects on ethanol, as well as 
sucrose consumption. All experimental procedures were approved by the University of North 
Carolina Institutional Animal Care and Use Committee (IACUC) and complied with the NIH 
Guide for Care and Use of Laboratory Animals (National Research Council, 1996). 
Binge-Like Drinking Procedures 
The “drinking in the dark” (DID) protocol involves a 4-day procedure and is an animal 
model of binge ethanol consumption (Rhodes et al., 2005). Throughout the present experiments, 
mice remain in their home-cages in the vivarium. Beginning 3 hours into the dark cycle, water 
bottles were removed from the home-cage and replaced with a bottle containing a solution of 
20% (v/v) ethanol. On days 1-3, ethanol bottles remained on the cages for 2 hours before 
removal and replacement with water bottles. On day 4 (the test day), procedures were the same 
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as on days 1-3 except mice had access to ethanol for 4 hours. Mice were exposed to 3 cycles 
(weeks) of the DID protocol with ethanol, or 3% sucrose in a separate experiment. 
Surgical Procedures:  
For cannulae placement surgeries, animals were anesthetized using a cocktail of xylazine 
(10 mg/kg) and ketamine (100 mg/kg) delivered intraperitoneally (1.5 mL/kg). Bilateral 26 
gauge guide cannulae (Plastics One; Roanoke, VA) were aimed at the CEA (AP: -1.06, ML: 
±2.50, DV: -4.64) or BLA (AP: -1.22, ML: ±2.9, DV: -4.75) using an Angle II Stereotax (Leica 
Instruments, Houston, TX) (Paxinos and Franklin, 2001). The measured distance between 
bregma and lambda were divided by 4.21mm, which is the average distance between these 
structures. This value was multiplied by the aforementioned coordinates to allow adjusted 
coordinates for mouse brain size. Coordinate adjustments were similar to previous studies 
(Moore & Boehm, 2009). After a week of recovery, animals were subjected to the DID 
procedure for three weeks or cycles. On the test day of week 3, 1-2 hours prior to alcohol (20%) 
or sucrose (3%) access, 1 ug of IL-6 receptor antagonist (cMR16-1, monoclonal IgG1 
neutralizing antibody, Genentech; San Francisco, CA) was dissolved in 0.3ul saline or control 
infusions of saline alone (0.3 ul) were bilaterally infused at a rate of 0.3 uL/min for one minute 
using a 1.0 ul Hamilton syringe (Reno, NV) similar to previous studies (Lowery-Gionta et al., 
2012). This 1ug cMR16-1 dose was chosen based on the piloting of a few effective doses, and 
based upon doses used in similar studies (Lowery-Gionta et al., 2012; Marshall et al., 2015). 
Injectors were left in the guide cannulae for an additional minute to allow proper diffusion away 
from the injector. Mice were handled and habituated to the infusion procedures at least 2 times 
prior to test day. Immediately after the 4 hour binge test, tail blood samples (5 µl) were collected 
to assess BECs with an alcohol analyzer (Analox Instruments, Lunenburg, MA).  At the 
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conclusion of all behavioral analyses injection placements were histologically verified using an 
identical volume of Alcian blue dye (0.3 uL/injection site) as the IL-6 receptor antagonist 
experiments. Any animals with unilateral or bilateral misses were excluded from data analyses. 
Data Analysis 
Two-way analyses of variance (ANOVAs) were used to assess between-group and 
within-group differences in binge-like ethanol consumption, or binge-like sucrose consumption. 
Independent samples t-tests were used to determine specific differences in hourly consumption 
between experimental and control groups. Significance was accepted at p<0.05; all data is 
presented as mean ± SEM. For antagonism data, some animals were excluded from analysis (due 
to mouse health or unilateral/bilateral cannula misses), which accounts for differences in degrees 
of freedom between similar analyses. 
Results 
 
IL-6R antagonism in the central amygdala (CEA) reduces binge-like ethanol consumption, 
but does not alter sucrose consumption  
Mice in Cohort 1 were exposed to three cycles of the DID procedure with 20% ethanol.  
There was a significant interaction between hours of consumption and treatment (F(3,39)=4.090, 
p=.013), an effect of hours of consumption(F=3,39=5.432, p=.003), and an effect of treatment 
(F(1,13)=5.715, p=.033. Essentially, mice who received IL-6R antagonist in the CEA 
demonstrated significantly reduced ethanol consumption during the first hour (p=.039), the third 
hour (p=.022), and in total consumption (p=.033) as expressed in grams per kilograms compared 
to saline treated controls (Figure 3.1A).  Mice in Cohort 2 were exposed to three cycles of the 
DID procedure with 3% Sucrose. Mice who received IL-6R antagonist in the CEA demonstrated 
a non-significant interaction of hours of consumption by treatment (F(3,60)=1.067, p=.370), and 
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a non-significant effect of hours of consumption (F(3,60)=2.615, p=.059). Most importantly, 
mice who received IL-6R antagonist in the CEA demonstrated no significant differences in 3% 
sucrose consumption as expressed in milliliters per kilograms compared to saline treated controls 
(F(1,20)=.465, p=.465), suggesting that IL-6R antagonism specifically affects ethanol 
consumption and not other salient reinforcers with calories (Figure 3.1B).   
IL-6R antagonism in the basolateral amygdala (BLA) does not alter binge-like ethanol 
consumption, or sucrose consumption  
Mice in Cohort 3 were exposed to three cycles of the DID procedure with either 20% 
ethanol, or 3% sucrose. Mice who received IL-6R antagonist in the BLA demonstrated a non-
significant interaction of hours of ethanol consumption by treatment group (F(3,30)=.813, 
p=.497), and a non-significant effect of hours of consumption (F(3,30)=1.312, p=.289). Most 
importantly, mice who received IL-6R antagonist in the BLA demonstrated no significant 
differences in ethanol consumption (F(1,10)=.004, p=.954), compared to saline treated controls 
(Figure 3.2A). Mice who received IL-6R antagonist in the BLA demonstrated a non-significant 
interaction of hours of sucrose consumption by treatment group (F(3,30)=.4813, p=.745), and a 
significant effect of hours of consumption (F(3,30)=6.474, p=.002). Furthermore, mice who 
received IL-6R antagonist in the BLA demonstrated no significant differences in sucrose 
consumption (F(1,10)=.274, p=.612), compared to saline treated controls (Figure 3.2B). 
Discussion 
Mice with a history of three binge-like ethanol drinking cycles that received IL-6R 
antagonist in the central amygdala demonstrated significantly reduced ethanol consumption 
during the first hour, the third hour, and in total consumption compared to saline treated controls. 
Mice that received IL-6R antagonism in the basolateral amygdala demonstrated no significant 
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differences in ethanol consumption as compared to saline treated controls, which suggests that 
IL-6 actions in the central amygdala but not the basolateral amygdala modulate ethanol 
consumption. This finding is especially significant because it suggests that possible drug 
diffusions from infusion site into adjacent regions are not causing this reduction in ethanol 
consumption. Also, since the basolateral amygdala has been previously found to be a critical 
region for IL-1R signaling (Marshall et al., 2016) this finding suggests that the basolateral 
amygdala is not a critical region for IL-6R signaling in the modulation of binge-like ethanol 
drinking. 
Follow up tests were run with sucrose to determine if the role of IL-6R signaling is 
specific to the modulation of ethanol consumption. Mice that experienced three binge-like 
sucrose drinking cycles that received IL6R antagonist in the central amygdala or the basolateral 
did not demonstrate differences in consumption versus saline treated controls, which suggests 
that IL-6 actions affect ethanol without impacting the rewarding sucrose consumption. This 
finding is also important for other reasons as well. Since the IL-6R antagonist only affected 
ethanol drinking when infused in the central amygdala and had no impact on sucrose 
consumption when infused in either amygdalar region, this effect acts as tool validation for the 
IL-6R antagonist (neutralizing antibody). If this effect were found with consumption of both 
fluids or in both regions that were tested, then there might be a possibility that a neutralizing 
antibody works by non-specifically altering all consumption wherever it is infused. However, the 
specificity of these IL-6R effects are in line with the known IL-6 actions and would not suggest 
the neutralizing antibodies are unsophisticated tools for altering IL-6 signaling. Future studies 
might use control antibodies for infusions as opposed to the (vehicle) saline infusions used 
within these novel studies, but given the specificity of these effects, alternative controls are not 
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expected to alter these particular findings. Indeed, both types of controls have been used 
previously in the literature (Xin et al., 2014; Narkbunnam et al., 2013), and a thorough search of 
the Pubmed article database revealed no demonstrated effects with control antibody infusions.  
MR16-1 neutralizing antibody has been used in a variety of applications since 1993. 
Tamura and colleagues (1993) reported that MR16-1 was used to demonstrate that IL-6 might 
play a role with osteoclast formation, which is part of a bone-maintenance process. Yoshida, 
Hashizume, and Mihara (2011) demonstrated that MR16-1 suppressed the onset of a laboratory 
induced model of arthritis. Narkbunnam and colleagues (2013) used MR16-1 and found that this 
drug is effective as an adjunctive therapy in reducing swelling and pathology associated with 
hemophilia. Arima and colleagues (2014) discovered that MR16-1 is effective for reducing 
inflammation in a mouse model of spinal cord injury. Also, Fujita and colleagues (2014) used 
MR16-1 to promote muscle regeneration in mice. A fuller characterization of MR16-1’s 
properties might be found in a paper by Okazaki and colleagues (2002). Indeed, this dissertation 
study and its associate experiments with IL-6R antagonist represent the first studies to use 
MR16-1 in the brains of living mice, and the first to explore IL-6R antagonism as a treatment for 
reducing ethanol consumption.  
Within these IL-6R antagonism experiments reported in this dissertation study, there 
were no observed immune consequences resulting from the cannulation procedure. Specifically, 
there were no behavioral abnormalities or inflammation attributable to cannulation to report. 
Additionally, the placement checks revealed no neurobiological anomalies surrounding the 
cannula tracts. In the basolateral IL-6R antagonism experiments, the mice were alive for 
approximately two months with no behavioral abnormalities to report from the cannulation or the 
IL-6R antagonism. One of the hallmark features of sickness is anhedonia, which is the loss of 
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enjoyment from pleasurable activities (Dantzer et al., 2008). Anhedonia is typically viewed by 
the reduced pursuit of pleasurable activities. These mice that received IL-6R antagonism in the 
basolateral or central amygdala demonstrated no reduction in consumption of the very rewarding 
sucrose solutions found within these experiments, as compared to saline-infused controls. 
Notably, these mice that received IL-6R antagonism in either amygdalar regions drank at similar 
levels to the unmanipulated mice drinking sucrose within the immunohistochemistry experiments 
reported in chapter two.  
  The fact that mice that received IL-6R antagonism in the basolateral or central amygdala 
demonstrated no reduction in sucrose consumption within these experiments, as compared to 
saline-infused controls is a critical finding to note for other reasons as well. IL-6 has been 
previously investigated in past research for its potential roles in stress processes, neuroendocrine 
processes, fever and sickness, and immunometabolism. Schobitz and colleagues (1995) 
administered exogenously generated IL-6 ICV to rodents and discovered that this increase in IL-
6 will raise body temperature, reduce locomotor activity, reduce food intake, but not alter water 
consumption. Lenczowski and colleagues (1999) also report that exogenous IL-6 administered 
ICV generated an HPA response as demonstrated by increased plasma adrenocorticotropic 
hormone and corticosterone expression. Furthermore, this research group reported that IL-6 also 
caused an increase in body temperature, but demonstrated no sickness behaviors. “Sickness 
behaviors”, within this context are referring to reduced social investigatory behavior and reduced 
locomotor activity. In Pal and colleagues (2014) review article, they describe the finding that 
increased plasma concentration of IL-6 was found in obese patients, and other supportive 
findings, but they also describe challenges with establishing the role of IL-6 in 
immunometabolism. Because IL-6 can be expressed as a muscle generated cytokine or myokine 
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as well as a cytokine, it becomes difficult to determine which variation of this immune 
messenger is playing a prominent role in immunometabolism. Within this dissertation study, the 
fact that IL-6R antagonism did not reduce sucrose consumption suggests that the central 
amygdala is not altering sucrose consumption due to sickness-induced anhedonia or reducing 
consumption of either ethanol or sucrose due to a global reduction of fluids with calories as 
might be found if IL-6 was acting through a purely metabolic process.  
 The findings discovered and reported within this chapter of the dissertation represent the 
first experiments to identify a critical brain region where IL-6 modulates binge-like ethanol 
drinking. These findings greatly extend the previous work on ethanol-induced IL-6 expression 
and provide a technical advantage over previous studies which used IL-6 KO mice. Yet, these 
findings beg the question, how does IL-6 alter ethanol consumption? What mechanisms are 
behind this reduce ethanol consumption? 
The central amygdala (CEA) is strongly implicated in both anxiety and alcohol use 
disorders (Gilpin et al., 2015). NPY actions within the CEA have been demonstrated to alter 
binge-like ethanol consumption (Sparrow et al., 2012), yet no known study has linked IL-6 to 
NPY mediated processes. CRF actions within the CEA have also been demonstrated to alter 
binge-like ethanol consumption (Lowery-Gionta et al., 2012), and CRF actions within the CEA 
have been implicated in mediating cytokine actions in other studies (Sternberg, 2006). Huang 
and colleagues (2010) reported that CRF released by stress acts on CRF-1 receptors within the 
CEA that sensitize anxiety-like behavior during withdrawal from chronic ethanol exposure. A 
review article by Breese and Knapp (2016) further describes the interactions between stress, 
anxiety, CRF, and neuroimmune signaling.  
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Following several binge exposures to alcohol, the abstinence from alcohol drinking 
causes an aversive withdrawal state. In this period of negative reinforcement, alcohol is then 
taken to reduce the aversive effects of the withdrawal experience (i.e., relapse). Cytokines have 
been implicated in the ethanol withdrawal experience, and IL-6 has been shown to play a role in 
emotionality, with IL-6 KO mice being more emotionally reactive to stimuli (Armario et al., 
1998; Butterweck et al., 2003). However, Heilig and colleagues (2010) note that this emotional 
component or change in affective processing is longer lasting and potentially more subtle than 
the anxiety, depression, and negative affect found with acute withdrawal.  The assessments 
within the dissertation experiments described in chapters 2 and 3 occurred immediately after 
voluntary ethanol consumption. Thus, it is more likely that a potential IL-6 role in an 
anxiety/stress modulation of ethanol consumption would be due to a change in affective 
processing and not an acute withdrawal effect. 
Alternatively, IL-6 could be interacting with GABA neurotransmission and affecting the 
rewarding or aversive properties of binge-like ethanol consumption. The central amygdala is 
primarily GABAergic, and is strongly implicated in both anxiety and alcohol use disorders 
(Gilpin et al., 2015). In a series of studies using IL-1 KO mice, IL-1 receptor antagonist, and 
recombinant IL-1ß, Bajo and colleagues (2014, 2015) established a role for IL-1 in the 
modulation of ethanol-induced GABAergic neurotransmission in the central amygdala. 
Interleukin-6 has been implicated to interact with GABA, but studies establishing the ethanol 
contribution to this interaction have not yet been reported (Garcia-Oscos et al., 2012; Gruol, 
2015; Hernandez et al., 2016). 
Finally, reduced sensitivity to ethanol (as demonstrated by increased sedative behaviors) 
is often associated with increased ethanol consumption in rodent models (Thiele et al., 2000). 
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The findings (reported in chapters 2 and 3) that IL-6 is upregulated within the central amygdala 
in response to three binge-like ethanol cycles, and that antagonism of the IL-6R reduces binge-
like ethanol consumption might suggest that cytokines play a role in ethanol sensitivity.   The 
following study, described in the next chapter, explored the role of brain IL-6 in ethanol-induced 
moderate sedation/ataxia in C57BL/6J mice, by antagonizing IL-6 receptor actions in the central 
amygdala brain region previously implicated in modulating neurobiological responses to ethanol.  
Mice were infused with saline or IL-6R antagonist and later exposed to an intraperitoneal 2 g/kg 
dose of 20% ethanol and tested on rotarod latency. This study was run with the objective to 
determine whether or not IL-6R antagonism reduces consumption through an alteration of 
ethanol sedation or sensitivity processes. This investigation into the role of IL-6 in ethanol 
sensitivity represents one of several possible mechanisms to explain the novel finding that IL-6 
can alter binge-like ethanol consumption.  
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Figure 3.1 Mice received central amygdala (CEA) cannulation and were exposed to three cycles 
of the DID procedure with either 20% ethanol, or 3% sucrose. (A) Mice who received IL-6R 
antagonist in the CEA demonstrated significantly reduced ethanol consumption during the first 
hour (p=.039), the third hour (p=.022), and in total consumption (F(1,13)=5.715, p=.033) as 
expressed in grams per kilograms compared to saline treated controls. (B) However, Mice who 
received IL-6R antagonist in the CEA demonstrated no significant differences in sucrose 
consumption as expressed in milliliters per kilograms compared to saline treated controls.  
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Figure 3.2 Mice received basolateral amygdala (BLA) cannulation and were exposed to three 
cycles of the DID procedure with either 20% ethanol or 3% sucrose. (A) Mice who received IL-
6R antagonist in the BLA demonstrated no significant differences in ethanol consumption as 
expressed in grams per kilograms compared to saline treated controls.  (B) Furthermore, Mice 
who received IL-6R antagonist in the BLA demonstrated no significant differences in sucrose 
consumption as expressed in milliliters per kilograms compared to saline treated controls. 
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Chapter 4 
Interleukin-6 receptor antagonism effects on moderate ethanol-induced sedation/ataxia 
Low level of response or sensitivity to ethanol, as evident by delayed intoxication or 
sedation, has been associated with high risk for later alcoholism (Shuckit, 1994). Shuckit and 
colleagues (2011) suggest that the low sensitivity to ethanol may be seen as both a genetic and 
environmental contributor to alcoholism. The genetic component lies in the fact that 
approximately 50% of low alcohol response is genetically mediated. The environmental 
component is due to the higher number of drinks needed to achieve the desired ethanol effects. 
Paralleling these facts, cytokines have been demonstrated to produce an environmental factor in 
ethanol drinking, (since ethanol drinking induces cytokines, see Chapter 2), and cytokine gene 
polymorphisms have been implicated with higher incidences of alcohol dependence (Liu et al., 
2009; Gonzalez et al., 2008). Furthermore, reduced sensitivity to ethanol is often associated with 
increased ethanol consumption in rodent models (Thiele et al., 2000). Thus, this converging 
evidence suggests that pro-inflammatory cytokines may play a role in ethanol sensitivity.    
Cytokines may generate a high sensitivity/sedation due to a potential over-response of 
cytokines which would then usher in sickness or sedation to cope with the cytokine response. In 
this scenario, cytokine antagonists would work to normalize the cytokine over-reaction. Wu and 
colleagues (2011) report that the high peripheral dose of 100 mg/kg/i.p. IL-1RA reduced 
ethanol-induced sedation (sleep time) and motor impairment. Additionally, this research team 
(2011) also reports that TLR4 KOs and Myd88 KOs (immune gene knock-out mice) show 
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reduced sedation and motor impairment than matched controls. Corrigan and colleagues (2014) 
also report that TLR2 KOs show minimal sedation behaviors in comparison to wild-type 
controls. Yet, high doses of antagonist or gene deletion may not present that best tools for 
assessing IL-1’s actions. Gene knockdown methods are preferable tools to avoid developmental 
or immune system defects, or compensations from never possessing the gene (KO mice). Also, 
gene knockdown methods allow temporal and spatial characterization or manipulation of these 
genes that is not easily achieved with KO mice or peripheral injections.  
In contrast to the previously mentioned studies, Vicente-Rodriguez and colleagues (2014) 
report that mutant mice that overexpress the cytokine pleiotrophin show enhanced ethanol 
preference and reduced sedation/ataxia in response to ethanol administration. As evident by these 
aforementioned studies, prior research has provided mixed results concerning the role of 
cytokines in ethanol sensitivity and sedation. Despite the mixed results regarding cytokines’ role 
in ethanol sensitivity and consumption, based upon previous studies (Shuckit, 1994; Shuckit et 
al.,  2011; Thiele et al., 2000), and the fact that IL-6R antagonist reduced ethanol consumption 
(chapter 3), it is predicted that IL-6R antagonist will increase ethanol sensitivity. 
The present study examined the role of brain IL-6 in ethanol-induced moderate 
sedation/ataxia in C57BL/6J mice, by antagonizing IL-6 receptor actions in the central amygdala 
brain region previously implicated in modulating neurobiological responses to ethanol.  Mice 
were infused with saline or IL-6R antagonist and later exposed to an intraperitoneal 2 g/kg dose 
of 20% ethanol and tested on rotarod latency. 
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Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were used in all 
experiments. Mice were approximately 6-8 weeks old and weighed between 20-25g at the 
beginning of experimental procedures. Mice were individually housed in polypropylene cages 
with corncob bedding and ad libitum access to standard rodent chow (Purina RMH 3000, 
Tekland, Madison, WI) and water, except where noted in experimental procedures. The colony 
rooms were maintained at 22ºC with a reverse 12-hr/12-hr light/dark cycle with lights out at 10 
a.m. One cohort was used for this study, which consisted of 12 mice that were previously used to 
explore CEA IL-6R antagonism’s effects on sucrose consumption. These 12 mice experienced 
only control saline infusions during this prior sucrose study. All experimental procedures were 
approved by the University of North Carolina Institutional Animal Care and Use Committee 
(IACUC) and complied with the NIH Guide for Care and Use of Laboratory Animals (National 
Research Council, 1996). 
Surgical Procedures:  
Mice were implanted with cannulae and experienced sucrose drinking and infusion 
procedures as described in chapter 3. At the conclusion of all behavioral analyses (described 
below) injection placements were histologically verified using an identical volume of Alcian 
blue dye (0.3 uL/injection site) as the IL-6 receptor antagonist experiments. Any animals with 
unilateral or bilateral misses were excluded from data analyses. 
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Sedation/Ataxia Procedures 
Accelerating rotarod test 
The rotarod apparatus (Ugo Basile Biological Research, Varese, Italy) consisted of a 3 
cm diameter horizontal rotating rod divided into five 6 cm sections by tan acrylic disks. The rod 
was rotated by a motor that accelerated from 0 to 40 rpm over the course of 5 min. For each trial, 
the mouse was placed on the stationary rod, which was then rotated until the mouse fell. Mice 
experienced one pre-test day consisting of 5 trials to establish an average baseline performance 
level for latency to fall from the rotarod. On test day, one hour and 5 minutes prior to the test, 
mice received either saline (0.3ul) or IL-6R antagonist, cMR16-1 (1ug/0.3ul), infused bilaterally 
into the central amygdala. Five minutes prior to rotarod testing, all mice received a 2.0 g/kg i.p. 
injection of 20% ethanol (w/v) mixed in isotonic saline. This 2.0 g/kg i.p. ethanol dose is based 
upon Rustay and colleagues’ (2003) study. Mice experienced 4 trials on the test day. This study 
was repeated the following week with flipped groups in a Latin Square design. The rotarod test 
was used to assess sensitivity to alcohol-induced sedation and motor incoordination (ataxia). 
Data Analysis 
Two-way analyses of variance (ANOVAs) were used to assess between-group and 
within-group differences in rotarod latency to fall (averaged over trials) over the course of the 
two days of rotarod testing. Independent samples t-tests were used to determine specific 
differences in rotarod latency (averaged over trials) between experimental and control groups on 
test day. Significance was accepted at p<0.05; all data is presented as mean ± SEM. Some 
animals were excluded from analysis (due to mouse health or unilateral/bilateral cannula misses), 
which accounts for differences in degrees of freedom between similar analyses. 
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Results 
 
IL-6R antagonism in the central amygdala (CEA) does not alter moderate sedation/ataxia 
The groups of mice that experienced saline infusions and the groups that experienced IL-
6R antagonist infusions over the two weeks were clustered by treatment and combined for 
further analysis. There was a non-significant interaction of days of sedation testing by latin order 
of exposure over the two weeks by treatment group (F(1,17)=.818, p=.378). There was a non-
significant interaction of days of sedation testing by latin order of exposure over the two weeks 
(F(1,17)=3.481, p=.079). There was a non-significant interaction of days of sedation testing by 
treatment group (F(1,17)=.052, p=.822). On test day, all mice demonstrated reduced average 
latency to fall compared to the pre-test day due to the ethanol administration (F(1,17)= 114.307, 
p<.001). There was a non-significant interaction of treatment groups over the two weeks 
(F(1,17)=.258, p=.618). There were no significant effects of latin order over weeks 
(F(1,17)=1.845, p=.192), and no significant effects of treatment group (F(1,17)=.524, p=.479) 
(Figure 4.1). These effects suggest that IL-6R antagonism in the central amygdala does not alter 
ethanol’s moderate sedative/ataxic properties. 
Discussion 
Mice underwent one pre-test day of rotarod training, and demonstrated no baseline 
differences between groups in latency to fall from the rotarod apparatus. On test day, mice 
received either saline or IL-6R antagonist infused into the central amygdala. Subsequently, all 
mice received a 2.0 g/kg i.p. injection of 20% ethanol. This i.p. injection dose of ethanol was 
chosen because this dose would generate similar blood ethanol concentrations as binge drinking 
in the DID paradigm would generate. Compare the 2.0 g/kg i.p. ethanol dose in Doremus-
Fitzwater and colleagues’ (2014) study and a cycle of DID in Lowery-Gionta and colleagues’ 
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(2012) study for reference. As would be expected from this injection, all mice showed a reduced 
latency to fall due to the ethanol injection. This suggests that the mice did experience the mild 
sedative/ataxic effects of a binge-level dose of ethanol. However, there were no test day 
differences in latency to fall between the mice that received IL-6R antagonist or saline infusions. 
These effects suggest that IL-6R antagonism in the central amygdala does not alter ethanol’s 
moderate sedative/ataxic properties. Thus, the mechanisms by which IL-6 modulates binge-like 
ethanol drinking in the CEA do not appear to involve the modulation of ethanol-induced 
sedation. 
Ethanol drinking has been previously shown to increase pro-inflammatory cytokine 
expression, and cytokine expression increases ethanol drinking. Based upon a review of the 
literature, it would seem that pro-inflammatory cytokines have an antagonistic relation with 
ethanol sensitivity/sedation. Thus, pro-inflammatory cytokines would be expected to lower 
sensitivity to sedation, and would increase ethanol consumption. Indeed, the anticipated effect 
was for the cytokine antagonist to increase the sedative properties of ethanol. However, the term 
sedation covers a spectrum of behaviors that range from the moderate sedation of ataxia to the 
heavy sedation that would cause a subject to fall asleep. Since the drinking in the dark paradigm 
generates the same blood ethanol concentrations as a 2.0 g/kg i.p. ethanol dose, and this same 
dose level is commonly used in ataxia studies (Wu et al., 2011; Vicente-Rodriguez et al., 2014), 
the moderate sedation found with ataxia seemed like the best sedation behavior to assess. 
The drinking in the dark (DID) paradigm is a great paradigm for generating binge level 
drinking, but it was not the chosen first step for assessing moderate sedation for a few reasons. 
Individual differences do exist between C57BL/6J mice in their total ethanol consumption, but 
typically the differences are minor. However, if the mice do not consume ethanol at similar 
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levels, then the interpretation of the IL-6R antagonist’s effects would be potentially confounded. 
Also, some mice will front load their drinking within their first two hours of their binge test day, 
while others might periodically consume ethanol over their four hour binge test. To administer 
the IL-6R antagonist without altering ethanol consumption, the antagonist would need to be 
administered subsequent to the DID procedures. Thus, the challenge would be giving the IL-6 
antagonist after all the mice with their respective drinking patterns have drunken to binge levels. 
Due to the individual differences in total ethanol consumption and the different ethanol 
consumption patterns, it seemed like the tidiest method would be to use i.p ethanol injections. If 
differences were found with this method, then a follow-up test would have used the DID 
procedure followed by the ataxia assay. However, the sedation assessment tests/trials would have 
needed to be calibrated since alcohol is typically applied intraperitoneally before tests, and not 
via the DID paradigm.  
The rotarod assay is a great method for assessing moderate sedation and ataxia, with a well-
established history of effectiveness. (See Rustay et al., 2002 & 2003; Rhodes et al., 2007; 
Philibin et al., 2008 & 2012; Cox et al., 2013) However, there are other sedations assays 
available for assessing the spectrum of sedative behaviors at the various other levels of sedation 
that exist. There are the direct behavioral observations of locomotor activity within an open field 
apparatus after an approximate 2.0 g/kg i.p. dose of ethanol (Breese et al., 1984). However, such 
a method can be mired with problems operationally defining variables, with the possibility of 
more subjective rather than objective scoring of a spectrum of sedative behaviors. Also, there are 
balance beam tests as well as grid tests which assess sedative behaviors after an approximate 2.0 
g/kg i.p. dose of ethanol. The balance beam tests measures footslips on the beam after ethanol 
administration.  However, there are issues with this assay too, such as finding the right 
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proportions in terms of mouse size in comparison to beam width, defining what constitutes a 
footslip, and accurately recording the amount of footslips can be challenging for assessments. 
The grid test is a test in which mice receive ethanol administration and are then placed on a mesh 
grid, and the mouse is assessed on the amount of time the mouse’s foot misses the grid and 
touches the floor beneath (Crabbe et al., 2003). However, some mice could get their feet caught 
in the grid, or end up awkwardly positioned due to the unstable grid surface, and end up messing 
up assessments. These general behavior assessments, balance beam tests, and grid tests are still 
used, but are typically used as supplemental measures with other sedation assessments. The 
balance beam test was intended to be used in conjunction with the rotarod tests within this 
dissertation study, but the negative results found with the rotarod test reduced the need for a 
supplemental test to further assess moderate sedative behaviors after a binge-level dose of 
ethanol.   
Indeed, the most popular method for studying sedation is through the loss of righting reflex 
(LORR) task. In this task, mice are typically given a high i.p. dose of ethanol 3.0-4.0 g/kg of 
20% ethanol. This dose is well above the consumptions levels in the DID procedure, and will 
cause the mice to fall asleep. Mice are then placed on their backs, and assessed on the amount of 
time it takes the mouse to flip over onto its four paws, within a predetermined time period. (See 
Thiele et al., 2000, 2002, 2003, Fee et al., 2004; Blednov et al., 2005; Wu et al., 2011; Corrigan 
et al., 2014). This LORR test is an effective test for assessing sedative behaviors, but would 
appear to be an inappropriate test for determining whether IL-6R modulates binge-like ethanol 
consumption via the moderate sedation that would be generated by the DID procedure. 
 In summary, it would appear that IL-6R signaling does not modulate binge-like ethanol 
consumption via alterations in ethanol sensitivity and its inherent effects with sedation. There are 
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other modalities that IL-6R signaling could be acting on to impact binge-like ethanol 
consumption. These modalities will be discussed further within the General Discussion of this 
dissertation. 
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Figure 4.1 Mice experienced sedation/ataxia procedures. Mice underwent one pretest day of 
rotarod training consisting of 5 trials. On test day, one hour and 5 minutes prior to the test, mice 
received either saline or IL-6R antagonist infused bilaterally into the central amygdala. Five 
minutes prior to rotarod testing, all mice received a 2.0 g/kg i.p. injection of 20% ethanol. Mice 
experienced 4 trials on the test day. This study was repeated the following week with flipped 
groups in a latin square design. All mice demonstrated reduced latency to fall from pre-test day, 
but demonstrated no significant group differences in test day rotarod performance due to drug 
treatment.  
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General Discussion 
Interleukin-6 is a pleiotropic cytokine that influences several processes involved with the 
maintenance and survival of an organism. Within this dissertation, IL-6 has been described as 
critical cytokine involved with modulating binge-like ethanol consumption. However, IL-6 plays 
a variety of roles in the body such as regulating inflammation, contributing to neurogenesis, as 
well as endocrine roles. This cytokine may be produced by neurons, microglia, astrocytes, or 
endothelial cells. (Erta, Quintana, & Hidalgo, 2012; Hunter, & Jones, 2015). IL-6 is a critical 
cytokine that controls the transition from innate to adaptive immune processing. However, the 
roles of IL-6 may be heavily context dependent (Erta, Quintana, & Hidalgo, 2012). IL-6’s role 
may depend on the level of inflammation in the affected regions. IL-6, in concert with sIL-6Rα 
has been found to modulate the transition between acute and chronic inflammation. IL-6 has 
been suggested to be protective in low levels, but to be proinflammatory during chronic 
inflammation. One way that IL-6 has been found to be protective is by inducing production of 
the anti-inflammatory interleukin-1 receptor antagonist (Gabay, 2006). It would seem by most 
accounts that IL-6’s main goal is to maintain homeostasis in the body.  
Interleukin-6 has three signaling pathways that it is known to act on within the body. The 
least relevant pathway to the topic of neuroimmune signaling is the role that IL-6 plays in the 
skeletal muscle system. In this system, IL-6 is produced as a myokine which is essentially a 
cytokine secreted by muscles. In this capacity, IL-6’s primarily role appears to be to reduce 
inflammation and enhance functionality within the muscles, as well as enter the blood stream and 
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impact the body’s metabolism. This, in turn, can have an impact on body mass and is presently 
investigated in obesity research. In fact, obesity is associated with chronic low-grade 
inflammation, and so IL-6 might be impacting this chronic inflammation. As a myokine, IL-6 
follows a different pathway of signaling and expression than as the cytokine IL-6 (Pal, Febbraio, 
& Whitham, 2014; Guijarro, Laviano, & Meguid, 2006).  
The two most relevant pathways that IL-6 acts on within the neuroimmune system are the 
classic signaling and the trans-signaling pathways. Classical signaling is when IL-6 binds to IL-
6R and gp130. Classical signaling helps maintain homeostasis and can be neuroprotective. In 
neurons, IL-6 can act as a neuromodulator. IL-6 has been found in the PVN and other regions of 
the hypothalamus, the hippocampus, and also the cerebellum. (Benrick, et al., 2009; Sallmann, et 
al., 2000; Aniszewska et al., 2015; Jankord et al., 2010).  IL-6 has been detected in both 
cholinergic and GABAergic neurons. IL-6 is considered a neuropoietic cytokine because it 
promotes neuronal survival. Additionally, IL-6 has been implicated in assisting long-term 
potentiation, improving spatial learning, as well as maintaining and modulating neurogenesis 
(Bowen, et al., 2011; del Rey et al., 2013; Juttler, Tarabin, & Schwaninger, 2002). Depending on 
the concentrations of IL-6, this cytokine can protect against NMDA excitotoxicity, which is a 
factor in chronic alcohol drinking. IL-6 may influence neurons directly, but may also act as a 
messenger between glia and neurons (Juttler, Tarabin, & Schwaninger, 2002). In fact, some 
preliminary research suggests that IL-6 may act pre-synaptically or post-synaptically to alter 
neurotransmitter release (Gruol, 2015; Crowley, Cryan, Downer, & O’Leary, 2016).  
Trans-signaling is when IL-6 binds with sIL-6R and gp130. Trans-signaling is largely 
responsible for chronic inflammation (and depression) since the pervasiveness of these binding 
elements allow IL-6 to affect cells that do not express IL-6R. In fact, IL-6 has also been 
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demonstrated to be a critical cytokine that modulates sickness behaviors such as reduction of 
social exploration, loss of body weight, and immobility (Bluthe et al., 2000). Selective 
antagonists that target IL-6 trans-signaling have been demonstrated to reduce sickness behaviors 
(Burton et al., 2013), and improve survival rates in mouse sepsis models (Barkhausen et al., 
2011). Trans-signaling has been suggested to be involved in gut permeability, which is one of the 
proposed ways that binge ethanol exposure has been proposed to cause cytokines to circulate and 
impact the neuroimmune system. Soluble gp130 is one of the endogenous antagonists to this 
trans-signaling. This antagonist works by competing with the gp130 protein for binding to the 
IL-6 complex (Maes, Anderson, Kubera, & Berk, 2014; Jostock et al., 2001).  
Exploring the therapeutic potential of Interleukin 6 antagonism 
 Given the potential roles of interleukin 6 (IL-6) in neuroimmune disorders and in binge 
drinking behaviors, IL-6 antagonism presents a promising method of reducing inflammation and 
binge-like drinking behaviors. However, potential strategies to target IL-6 signaling should 
consider whether the protective neurotransmitter-like, homeostatic classical IL-6 system will be 
impacted or if the pro-inflammatory trans-signaling IL-6 system will be impacted by these 
interventions. One antagonist that has been prominently featured is tocilizumab (also known as 
MRA), which is an antibody that targets the IL-6 receptor. This drug is often prescribed as 
treatment for arthritis and other chronic inflammatory diseases. This drug inhibits both classical 
and trans-signaling. Another compound that is currently under investigation is the engineered 
sgp-130fc protein which prevents gp-130 from binding to the IL-6 complex by competitively 
binding with the IL-6 complex, much like the aforementioned endogenous sgp130 antagonist. In 
turn, this antagonist only blocks the IL-6 trans-signaling and not the classical IL-6 signaling 
(Hunter, & Jones, 2015; Jostock et al., 2001). This sgp-130fc compound inhibits only trans-
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signaling at low concentrations, but will inhibit classical signaling as well at high concentrations 
(Garbers et al., 2011). However, at the time of this writing neither compound was available for 
research purposes. 
Finally, the third major compound under investigation is MR16-1 (also known as BP-
5875). Okazaki and colleagues (2002) report that MR16-1 interferes with IL-6’s binding to the 
soluble IL-6 receptor by competitively binding to this receptor, which is the principal receptor 
active during trans-signaling.  However, this compound may have the potential to neutralize 
membrane bound IL-6 receptors as well. MR16-1 has been used previously in studies of arthritis 
and other chronic inflammation diseases. In fact, MR16-1 has been used to treat mouse models 
of spinal cord injury. This drug has been shown to reduce inflammation to spare tissues, and 
decrease the possibility of glial scar formations within this mouse model of spinal cord injury 
(Arima et al., 2014). Given the accessibility of this compound, and this compound’s preferential 
action on trans-signaling, a variation of this compound was used here for studies exploring the 
role of IL-6 in alcohol consumption and sedation behaviors. The version of this compound used 
for these studies was a chimeric MR16-1 (cMR16-1) which was determined to be especially 
effective in mouse models and will not cross-react with human IL-6R (Fujita et al., 2014).  
The challenges of site-specific antagonism 
The blood-brain-barrier is an effective barrier for preventing pathogens from entering the 
brain, but this barrier also presents a significant challenge for drug therapies to enter and affect 
behavioral disorders. Several approaches to central nervous system drug delivery have been 
proposed and explored throughout the years, with varying costs and other considerations, as is 
described by William Banks (2016). While drug delivery still remains a challenge, in the 
laboratory setting there is one method that has a long, proven history of effectiveness with 
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laboratory animals, which is the direct infusions of drug into the brain via implanted cannulas. In 
1994, Bluthe and colleagues used interleukin-1 receptor antagonist (IL-1RA) administered 
intracerebroventricularly (ICV) in CD1 mice to reduce the deficits in social interactions caused 
by prior infusion of TNF-α. Maier and Watkins (1995) also used ICV IL-1RA to block fear 
conditioning in Sprague-Dawley rats. Goshen and colleagues (2007) used ICV IL-1ß or IL-1RA 
on mice with a C57 background to demonstrate that a slight increase in IL-1ß will improve 
contextual memory in a fear conditioning paradigm, but too little or too much IL-1ß will impair 
contextual memory. Arakawa and colleagues (2009) used IL-1RA to rescue the reduction in 
social behavior that results from a prior foot-shock stressor. Also in 2009, Moore and Boehm 
used site-specific infusions of the GABA-B agonist, baclofen, into the anterior ventral tegmental 
area (VTA) to reduce binge-like ethanol consumption of C57BL/6J mice within the DID 
paradigm. This group discovered that these infusions will not affect water consumption, nor will 
the infusions in the adjacent posterior VTA affect binge-like ethanol consumption. Also, this 
group generated a formula with the assistance of a mouse brain atlas to adjust for the drift in the 
stereotaxic brain coordinates that may occur due to an individual mouse’s unique features, or the 
drift that may occur due to age-related brain/skull growth.  
The Thiele lab has used similar methods in their work exploring CRF actions in binge-
like ethanol drinking. This group has found that antagonism of the CRF 1 receptor reduced 
binge-like ethanol drinking in C57BL/6J mice when this antagonist is infused in the central 
amygdala but not the basolateral amygdala (Lowery-Gionta, et al., 2012). In fact, recently this 
group has performed a study exploring the role of IL-1ß in binge-like ethanol drinking. In 
contrast to the CRF findings, IL-1 receptor antagonism via IL-1RA in the basolateral amygdala, 
but not the central amygdala reduced binge-like ethanol drinking of C57BL/6J mice within the 
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DID paradigm. Additionally, IL-1RA did not alter sucrose drinking or open-field activity. 
Notably, Fluoro-Jade® C labeling indicated that multiple binge-like alcohol cycles did not cause 
neuronal death suggesting that cytokines actions are not modifying behavior by killing neurons 
(Marshall, et al, 2015).  
All of these previous studies in other neuroimmune labs used cannulation, with no reports 
of lasting immune consequences of the neurobiological or behavioral nature resulting from the 
cannulation procedure. Other laboratories that use bilateral cannulations have not reported any 
lasting immune consequences. For example, Xin and colleagues (2014) used BDNF-neutralizing 
antibody site-specifically to demonstrate a critical role of BDNF in the basolateral amygdala for 
conditioned taste aversion. Most importantly, our lab did not observe immune consequences in 
our prior study which used bilateral cannulas directed at the central or basolateral amygdala. 
However, while our laboratory and others have not specifically experimentally tested for 
immune consequences from cannulation, there has been no report of sickness or other noticeable 
immune actions (site inflammation) resulting from this manipulation. Our study used IL-1RA 
directed at both of these amygdalar regions to determine that the basolateral amygdala was the 
critical region for IL-1R mediated ethanol consumption. Also of note, IL-1RA infusion into the 
basolateral amygdala did not alter sucrose consumption or open-field locomotor activity. These 
negative results in the open-field assay suggest that IL-1RA is not affecting general locomotor 
activity or the mouse anxiety this assay is designed to assess (Marshall et al., 2016). Indeed, 
cannulation may generate a transient immune response, but this would be resolved by allowing 
mice to have at least a week of recovery prior to further stimulus. Not surprisingly, a week of 
recovery is a fairly standard practice for labs that perform surgeries. 
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IL-6 antagonism in the brain is still a fairly new strategy that has not been explored in 
great detail until this dissertation. Noda and colleagues (2013) used a monoclonal antibody 
against human IL-6R (known as tocilizumab) in a mouse model which encouraged brain tumor 
growth in nude mice. This antibody was applied intravenously for twice a week for three weeks, 
which effectively reduced the tumor size compared to mice exposed to human IgG antibody 
control infusions. Burton and colleagues (2013) is the only other group known to use central IL-6 
antagonism as a strategy for exploring IL-6 actions in the brain. This group used soluble gp130, a 
known inhibitor of IL-6 trans-signaling, which they infused ICV to reduce LPS induced 
neuroinflammation and sickness behaviors in aged BALB/c mice.  
Summary of Current Findings 
Within the immunohistochemistry studies reported here, there were several discoveries 
on the expression of IL-6 in response to sucrose or ethanol consumption. In fact, relative to water 
drinking controls, IL-6 immunoreactivity (IR) is up-regulated in the central amygdala and the 
paraventricular nucleus of the (PVN) hypothalamus of mice with a history of three binge-like 
ethanol drinking cycles. This effect is not found in mice that were only exposed to one binge-like 
ethanol drinking cycle. In a separate study comparing sucrose versus water drinking induced IL-
6 IR, no significant differences with IL-6 IR were found in the central amygdala or the PVN. 
This sucrose consumption finding suggests that IL-6 has unique actions in response to ethanol 
consumption, which are not found with consumption of other salient reinforcers. Additionally, 
IL-6 IR is unaffected in the (adjacently located) basolateral amygdala of mice with a history of 
three binge-like ethanol drinking cycles. Notably, IL-6 IR is not increased in the BNST or the 
nucleus accumbens in response to one or three cycles of binge-like ethanol drinking. This seems 
to indicate that IL-6, in response to binge-like ethanol drinking, is not altered in these regions of 
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the reward circuitry indicated in Koob’s (2003) allostatic model of alcohol addiction. Also, IL-6 
IR is not increased in the lateral septum in response to one or three cycles of binge-like ethanol 
drinking. The lateral septum is a non-classical reward related region of interest that has been 
regarded as important for ethanol consumption as described by Ryabinin, Bachtell, and 
colleagues (2003, 2003, & 2008). Additionally, Breese and colleagues (1984) described the 
septum as a region that is important for mediating ethanol induced motor impairment or sedative 
behaviors. However, the significant effects in the central amygdala and the PVN suggest that 
increased IL-6 expression in the brain is site-specific in response to alcohol consumption. The 
fact that three cycles or weeks of ethanol exposure, and not one week of ethanol exposure, are 
needed to produce the enhanced IL-6 expression over the water controls suggests that IL-6 
actions are more relevant in subjects with an extended history of binge-like ethanol consumption.  
The IL-6R antagonism studies revealed that mice with a history of three binge-like 
ethanol drinking cycles that received IL-6R antagonist in the central amygdala demonstrated 
significantly reduced ethanol consumption during the first hour, the third hour, and in total 
consumption compared to saline treated controls. Mice that received IL-6R antagonism in the 
basolateral amygdala demonstrated no significant differences in ethanol consumption as 
compared to saline treated controls, which suggests that IL-6 actions in the central amygdala but 
not the basolateral amygdala modulate ethanol consumption. This finding is especially 
significant because it suggests that possible drug diffusions from infusion site into adjacent 
regions are not a factor. Also, since the basolateral amygdala has been previously found to be a 
critical region for IL-1R signaling (Marshall et al., 2016) this finding suggests that the 
basolateral amygdala is not a critical region in IL-6R signaling.  
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Follow up tests were run with sucrose to determine if IL-6R signaling will only critically 
modulate ethanol consumption. Mice that experienced three binge-like sucrose drinking cycles 
that received IL6R antagonist in the central amygdala or the basolateral did not demonstrate 
differences in consumption versus saline treated controls, which suggests that IL-6 actions affect 
ethanol without impacting the rewarding sucrose consumption. This finding is also important for 
other reasons as well. Since the IL-6R antagonist only affected ethanol drinking when infused in 
the central amygdala and had no impact on sucrose consumption when infused in either 
amygdalar region, this effect acts as tool validation for the IL-6R antagonist (neutralizing 
antibody). If this effect were found with consumption of both fluids or in both regions that were 
tested, then there might be a possibility that a neutralizing antibody works by non-specifically 
altering all consumption wherever it is infused. However, the specificity of these IL-6R effects 
are in line with the known IL-6 actions and would not suggest that neutralizing antibodies are 
unsophisticated tools for altering IL-6 signaling.  
The IL-6R antagonism studies also explored the role that IL-6 might play in moderate 
ethanol-induced sedation. In these studies, mice underwent one pre-test day of rotarod training, 
and demonstrated no baseline differences between groups in latency to fall from the rotarod 
apparatus. On test day, mice received either saline or IL-6R antagonist infused into the central 
amygdala. Subsequently, all mice received a 2.0 g/kg i.p. injection of 20% ethanol. This i.p. 
injection dose was chosen because this dose would generate similar blood ethanol concentrations 
as binge drinking in the DID paradigm would generate. As would be expected from this 
injection, all mice showed a reduced latency to fall due to the ethanol injection. This suggests 
that the mice did experience the mild sedative/ataxic effects of a binge-level dose of ethanol. 
However, there were no test day differences in latency to fall between the mice that received IL-
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6R antagonist or saline infusions.  To confirm this effect, this study was repeated the following 
week with flipped groups in a Latin Square design. In week two, there were no baseline 
differences in latency to fall on pre-test day. On test day, all mice demonstrated reduced latency 
to fall compared to the pre-test day due to the ethanol administration, but demonstrated no 
significant group differences in test day rotarod performance due to the drug treatment.  
The groups that experienced saline infusions and the groups that experienced IL-6R 
antagonist infusions over the two weeks were then clustered by treatment and combined for 
further analysis. The combined groups demonstrated no baseline differences on latency to fall on 
pre-test day. On test day, all mice demonstrated reduced latency to fall compared to the pre-test 
day due to the ethanol administration, but demonstrated no significant group differences in test 
day rotarod performance due to drug treatment. Despite the switching of groups, and the second 
dose of ethanol a week later, there were no group differences in ethanol induced sedation/ataxia. 
These effects suggest that IL-6R antagonism in the central amygdala does not alter ethanol 
consumption by altering ethanol’s moderate sedative/ataxic properties. 
Potential cytokine roles during the escalation of binge alcohol drinking into alcohol 
dependence 
 
In consideration of the cytokine roles in the brain in response to normal and/or ethanol 
modulated processes, there is the implication that pro-inflammatory cytokine expression 
increases binge-like ethanol drinking. One model that has been postulated to account for the 
actions of the central cytokines within the pathway to dependence or addiction is the Allostasis 
model developed by Dr. George Koob. Homeostasis is characterized by the bodily processes that 
work to maintain the functionality and survival of an organism. Allostasis refers to the process 
where the same adaptive processes that work within homeostasis become dysregulated and these 
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adaptive processes change to attain stability, yet these changes push the regulatory systems 
outside the normal set-point into a potentially pathological set-point (Koob, 2003; Koob & Le 
Moal, 2001). Potentially the impairment in the homeostatic role of IL-6 might be responsible for 
the inability of the homeostatic mechanisms to attain the original normal set-points. 
The descent into alcohol addiction is characterized by experiences of positive and 
negative reinforcement. At first, alcohol activates the brain reward systems and generates a 
pleasurable experience. This period of positive reinforcement causes the alcohol user to binge 
drink alcohol in pursuit of the initial pleasures of alcohol use. Yet, as the body adapts to the 
continued binge exposures of alcohol, the body does not respond in the same ways to this drug. 
After several binge exposures to alcohol, cessation of alcohol drinking (abstinence) causes the 
aversive withdrawal state. In this period of negative reinforcement, alcohol is then taken to 
reduce the aversive effects of the withdrawal experience (i.e., relapse). Cytokines have been 
implicated in the ethanol withdrawal experience, and Breese and colleagues (2008) demonstrated 
that cytokine pre-exposure can sensitize this ethanol-induced anxiety experience. Notably, IL-6 
has been shown to play a role in emotionality, with IL-6 KO mice being more emotionally 
reactive to stimuli (Armario et al., 1998; Butterweck et al., 2003). However, IL-6 expression has 
also been found to increase in the hippocampus of C57BL/6J mice in response to stressors that 
are used for depression tests (Chourbaji et al., 2006). Whether or not IL-6 is interacting with 
emotions or stress responses, independently or together, in reaction to alcohol is yet to be 
determined.   
Conceptually, negative affect or emotional states could drive the descent into alcohol 
addiction. However, Heilig and colleagues (2010) note that this emotional component or change 
in affective processing is longer lasting and potentially more subtle than the anxiety, depression, 
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and negative affect found with acute withdrawal. Frequent binges followed by their withdrawals 
have been found to exacerbate the acute withdrawal effects which have been demonstrated to 
cause the alcohol abuser to increase voluntary ethanol consumption as well as become more 
reactive to stress. Yet, measuring the anxiety that is correlated with these phenomena is 
complicated and will likely need multiple assays to provide concrete answers on the anxiety 
roles. The subtle neuroadaptations underlying this process have been suggested to be related to 
HPA activation or CRF activity. Notably, stress has been found to be an adequate substitute for 
multiple binge cycles (Breese et al., 2005). These findings suggest that anxiety and stress might 
both by acting on binge alcohol drinking behaviors.  
In support of these stress roles in ethanol consumption, Knapp and colleagues (2011) 
describe a series of experiments exploring the cytokine interactions with stress and alcohol 
consumption. Restraint stress elevated TNF-α in whole brain ELISA assessments. TNF-α 
infusions into the central amygdala (CEA) increased ethanol-induced withdrawal anxiety, as was 
assessed by a social interaction test. Separately, a CRF1 antagonist administered peripherally 
prior to TNF-α or MCP-1 ICV infusions reduced ethanol-induced withdrawal anxiety. Together, 
these two infusion experiments suggest that CRF actions, and not HPA activation, might be 
underlying these ethanol withdrawal effects. Other studies have supported the role of the HPA 
axis influencing alcohol consumption (Vendruscolo et al., 2012), but ultimately concluded that 
CRF activity was more critical for ethanol consumption (Lowery et al., 2010; Koob, 2010). A 
later study found that a chronic ethanol diet generated increases in high-mobility group box 1 
(HMGB1) mRNA 24 hours after cessation from ethanol, as compared to rodents exposed to a 
control diet. HMGB1 has been previously implicated as mediating stress-induced cytokines, and 
so this research group hypothesizes that this expression might be due to ethanol-induced 
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withdrawal effects. In a separate experiment within the same study, this group discovered that an 
HMGB1 or CRF1 antagonist will reduced ethanol-induced expression of the cytokines (MCP-1, 
IL-1β, and TNF-α) and HMGB1 24 hours after the last ethanol administration (Whitman et al., 
2013). A good review article by Breese and Knapp (2016) describes the interactions between 
stress, anxiety, CRF, and neuroimmune signaling. Several examples were cited referring to stress 
leading to relapse drinking, stress leading to greater alcohol drinking, and the frequent co-
occurrence of alcohol abuse with psychiatric/stress disorders. Also, see Becker and colleagues 
(2011) for a review of stress effects on ethanol consumption. Karlsson and colleagues (2016) 
used to a double knockout mouse which had deletions of IL-1R1 and TNF-1R gene to investigate 
stress induced drinking due to a social defeat stressor. In their model, double KO mice did not 
exhibit the stress-induced increases in the ethanol consumption found in control mice.  
With the assays used for my dissertation research, the brains were retrieved immediately 
after the “drinking in the dark” paradigm, and so the IL-6 effects are not likely to be due to acute 
withdrawal stress effects but IL-6 might be impacted by the neuroadaptations caused by the 
stress and anxiety found by a history of binge ethanol and withdrawal episodes.    
 In the Allostasis model, binge cycles of alcohol use and withdrawal alter the normal set-
points into an allostatic state. While in the allostatic cycle, prior set-points are no longer 
attainable. Thus, the perpetual cycles eventually descend into a pathological state (Koob & Le 
Moal, 2001; Koob, 2003; Koob, 2008). These cycles are easily represented by multiple binge-
like cycles of DID in mice. Mice are expected to demonstrate similar behaviors to humans in 
response to this extended binge-like alcohol exposure. In fact, some studies from the Thiele & 
Lysle laboratories have supported a potential role that cytokines could be playing over the course 
of several binge alcohol cycles. For example, Marshall and colleagues (2015) demonstrated that 
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IL-1ß will show alcohol-induced expression after one binge cycle in the central amygdala and 
the basolateral amygdala, but will only show this enhanced expression in the basolateral 
amygdala after three cycles. Marshall and colleagues (2016) discovered that the anti-
inflammatory cytokine IL-10 is only increased after three binge cycles, and only in the 
basolateral amygdala. Adding to these published results, this dissertation work establishes that 
IL-6 will show alcohol-induced expression after three binge cycles, but only in the PVN and the 
central amygdala. 
In the Allostasis model, the reward circuitry involved with alcohol reinforcement 
includes the extended amygdala (including the BNST), the lateral hypothalamus, the nucleus 
accumbens, and the ventral tegmentum area (VTA) (Koob, 2003).  These same brain areas (with 
the exception of the VTA) have been found to host interactions between the neurotransmitters 
(serotonin and dopamine) implicated in the alcohol Allostasis model and the cytokines IL-1(β), 
IL-6, and TNF-α (Brebner, Hayley, Zacharko, Merali, & Anisman, 2000).  Additionally, the 
central amygdala was found to host interactions between TNF-α and GABA (Knapp et al, 2011). 
While IL-6 expression was not increased in the other aforementioned rewards regions within this 
dissertation, IL-6 was increased in the central amygdala. Notably, the central amygdala has also 
been a region implicated in the moderation of negative affect, stress, and anxiety behaviors. 
Recently, Pleil and colleagues (2015) discovered that mice that had been exposed to four cycles 
of chronic intermittent ethanol and then were tested 48 hours later showed increased anxiety as 
determined by a marble burying task. Associate with the increased anxiety was an inhibition of 
signaling in the central amygdala indicative of a reduced capacity for action potential firing.  
The innate immune response to pathogens has been found to have interactions with the 
opioids, glucocorticoids, NPY, and CRF throughout the central nervous system (Sternberg, 
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2006). Thus, it could be argued that cytokines (such as the homeostatic IL-6) interact with key 
neurotransmitters and neuropeptides in regions implicated in alcohol reinforcement processes. In 
fact, IL-6 could be interacting with GABA neurotransmission and affecting the rewarding or 
aversive properties of binge-like ethanol consumption. The central amygdala is primarily 
GABAergic, and is strongly implicated in both anxiety and alcohol use disorders (Gilpin et al., 
2015). Indeed GABA could be altering CRF expression independently following ethanol 
exposure (as suggested in Herman et al., 2016), but it is likely that cytokines also contribute to 
this process. In a series of studies using IL-1 KO mice, IL-1 receptor antagonist, and 
recombinant IL-1ß, Bajo and colleagues (2014, 2015) established a role for IL-1 in the 
modulation of ethanol-induced GABAergic neurotransmission in the central amygdala. 
Interleukin-6 has been implicated to interact with GABA, but studies establishing the ethanol 
contribution to this interaction have not yet been reported (Garcia-Oscos et al., 2012; Gruol, 
2015; Hernandez et al., 2016). While the framework for the allostatic model is not complete, 
given the cited evidence, it seems likely that cytokines contribute vitally to alcohol 
dependence/pathology. 
Future Directions 
Upcoming studies can further characterize the potential roles of the cytokines at the 
various stages of binge-like ethanol consumption and ethanol-mediated behaviors in the descent 
into dependence. Also, IL-6 specifically might be tested for potential stress or anxiety roles it 
might be utilizing to mediate ethanol consumption. In pursuit of this aim, interactions between 
IL-6 and CRF might also be explored to further establish the interfaces between cytokines and 
neuropeptides. Alternatively, interactions between IL-6 and GABA could be explored for 
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potential roles that this interface might have in modulating the rewarding or aversive aspects of 
ethanol consumption. 
New tools are on the horizon for imaging the cytokines with better sensitivity, as well as 
greater temporal and spatial resolution than existing immunoassays like immunohistochemistry. 
Bead assays with optical fiber-based sensors, and microfluidic devices have been suggested to be 
critical tools towards the goal of in vivo detection of the various cytokines acting in response to 
immune challenges (Liu et al., 2016). Other emerging imaging tools for characterizing immune 
signaling include nanoparticles, Raman spectroscopy, RNA probes, and MALDI imaging 
(Jacobsen et al., 2016). Together, some of these tools may inform future studies on cytokine 
dynamics depending on their practical and effective utility in characterizing immune challenges, 
such as binge alcohol drinking.   
Future studies using IL-6R antagonism might use control antibodies for infusions as 
opposed to the (vehicle) saline infusions used within these novel studies, but given the specificity 
of these effects, alternative controls are not expected to alter these particular findings. Indeed, 
both types of controls have been used previously in the literature (Xin et al., 2014; Narkbunnam 
et al., 2013), and a thorough search of the Pubmed article database revealed no demonstrated 
effects with control antibody infusions. Also, IL-6 might also be antagonized through other 
methods as technology improves. For example: antisense oligonucleotides, mRNA, siRNA, and 
microRNA gene therapies might prove useful for the antagonism of the various elements of the 
IL-6 pathway to determine which critical IL-6 gene(s) might be impacting binge-like ethanol 
drinking. However, these strategies are somewhat limited by the current strategies for delivering 
these exogenous agents to the critical brain regions for modulating the binge ethanol drinking. 
Indeed, the challenges, the current progress, and the future directions of these genetic therapies 
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are explored in greater detail by Yin and colleagues (2014). These genetic strategies may in fact 
prove to be effective strategies for antagonizing IL-6 with minimal or possibly no cannulation of 
experimental animals in the near future. 
Finally, while there has been a growing focus on the behavioral effects of cytokine 
actions within the brain, there is much less focus on what neuronal mechanisms that cytokines 
like IL-6 might be impacting downstream from the IL-6 receptor activation. This presents 
another potential avenue of exploration for future studies. To review what is known about IL-6 
actions, IL-6 may be produced by neurons, microglia, astrocytes, or endothelial cells. IL-6 plays 
a variety of roles in the body such as regulating inflammation, contributing to neurogenesis, as 
well as endocrine roles.  (Erta, Quintana, & Hidalgo, 2012; Hunter, & Jones, 2015). IL-6 is a 
critical cytokine that controls the transition from innate to adaptive immune processing. 
However, the roles of IL-6 may be heavily context dependent (Erta, Quintana, & Hidalgo, 2012). 
IL-6’s role may depend on the level of inflammation in the affected regions. IL-6, in concert with 
sIL-6Rα has been found to modulate the transition between acute and chronic inflammation.  
The two most relevant pathways that IL-6 acts on within the neuroimmune system are the 
classic signaling and the trans-signaling pathways. Classical signaling is when IL-6 binds to IL-
6R and gp130. Classical signaling helps maintain homeostasis and can be neuroprotective. 
Trans-signaling is when IL-6 binds with sIL-6R and gp130. Trans-signaling is largely 
responsible for chronic inflammation (and depression) since the pervasiveness of these binding 
elements allow IL-6 to affect cells that do not express IL-6R. (Erta, Quintana, & Hidalgo, 2012).  
 In neurons, IL-6 can act as a neuromodulator. IL-6 has been detected in GABAergic 
neurons, and IL-6R has also been found to express within CRF neurons (Juttler, Tarabin, & 
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Schwaninger, 2002; Benrick et al., 2009). IL-6 is present in some CRF neurons, but many CRF 
neurons don’t express IL-6R which suggests that trans-signaling IL-6 mechanisms might be 
responsible for widespread IL-6 expression in CRF neurons.  Furthermore, IL-6 is critical in 
prolonged sickness and infections due to its role in sustaining an extended activation of CRF 
neurons in the modulation of the HPA axis (Vallieres, & Rivest, 1999).  However, IL-6 is 
considered a neuropoietic cytokine because it promotes neuronal survival. Additionally, IL-6 has 
been implicated in assisting long-term potentiation, improving spatial learning, as well as 
maintaining and modulating neurogenesis (Bowen, et al., 2011; del Rey et al., 2013). Depending 
on the concentrations of IL-6, this cytokine can protect against NMDA excitotoxicity, which is a 
factor in chronic alcohol drinking. (Juttler, Tarabin, & Schwaninger, 2002).   
The central amygdala is primarily GABAergic, and is strongly implicated in both anxiety 
and alcohol use disorders (Gilpin et al., 2015). Indeed GABA could be altering CRF expression 
independently following ethanol exposure (as suggested in Herman et al., 2016), but it is likely 
that cytokines also contribute to this process. Also, Partridge and colleagues (2016) determined 
through a series of stress related experiments that GABA is the principal co-transmitter in CRF 
neurons within the central amygdala. In a series of studies using IL-1 KO mice, IL-1 receptor 
antagonist, and recombinant IL-1ß, Bajo and colleagues (2014, 2015) established a role for IL-1 
in the modulation of ethanol-induced GABAergic neurotransmission in the central amygdala. 
Interleukin-6 has been implicated to interact with GABA, but studies establishing the ethanol 
contribution to this interaction have not yet been reported (Garcia-Oscos et al., 2012; Gruol, 
2015; Hernandez et al., 2016). 
 While there are still many unknown elements of the IL-6 actions within the neurons, 
there has been some progress with the intracellular mechanisms. IL-6R receptor activation at the 
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membrane produces pronounced transcription of the STAT3 and minor production of the STAT1 
proteins in the cell, which suggests an IL-6 impact on the JAK/STAT pathway since the JAK2 
protein is necessary to activate the STAT3 pathway. Additionally, IL-6 produced 
phosphorylation of p42/44 MAPK, which suggests an IL-6 impact on the MAPK pathway 
(Gruol, 2015; Garcia-Oscos et al., 2015; Schumann et al., 1999). Fang and colleagues (2013) 
used PI3K protein inhibitors to demonstrate that IL-6 also signals through the PI3K pathway. 
(See Figure 5.1 for a schematic of IL-6 neuronal actions) Garcia-Oscos and colleagues (2015) 
suggest a complex role for IL-6 in its interactions with GABAergic signaling that is dependent 
on the levels and types of IL-6 activations. Trans-signaling is believed to be the dominant form 
of signaling within the neuron due to the soluble IL-6R’s ability to impact many neurons that do 
not contain, or minimally express membrane bound IL-6R. Each of these pathways has been 
implicated with cell health, inflammation, and synaptic plasticity memory mechanisms. Indeed, 
future studies could explore how a history of binge-like ethanol consumption may impact the IL-
6 neuronal mechanisms that are believed to be underlying the CRF/GABA neuronal interactions 
within the central amygdala. 
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Figure 5.1 A schematic of Interleukin-6 neuronal actions. Converging evidence suggests that IL-
6 actions within CRF/GABA neurons of the central amygdala may be underlying the binge-like 
ethanol drinking effects found within this dissertation. This schematic shows the known 
JAK/STAT, MAPK, and PI3K pathways that IL-6 impacts within neurons. 
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